US20210038520A1 - Multiparticulate formulations of cannabinoids - Google Patents
Multiparticulate formulations of cannabinoids Download PDFInfo
- Publication number
- US20210038520A1 US20210038520A1 US17/081,189 US202017081189A US2021038520A1 US 20210038520 A1 US20210038520 A1 US 20210038520A1 US 202017081189 A US202017081189 A US 202017081189A US 2021038520 A1 US2021038520 A1 US 2021038520A1
- Authority
- US
- United States
- Prior art keywords
- composition
- release
- particles
- cannabinoid
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 497
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 150
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 150
- 229940065144 cannabinoids Drugs 0.000 title description 13
- 238000009472 formulation Methods 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract description 239
- 239000003814 drug Substances 0.000 claims abstract description 131
- 239000013543 active substance Substances 0.000 claims abstract description 108
- 238000013265 extended release Methods 0.000 claims abstract description 82
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 68
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 97
- 239000011324 bead Substances 0.000 claims description 92
- 239000004094 surface-active agent Substances 0.000 claims description 82
- 229940079593 drug Drugs 0.000 claims description 62
- 239000003795 chemical substances by application Substances 0.000 claims description 60
- 229920000642 polymer Polymers 0.000 claims description 51
- 239000000377 silicon dioxide Substances 0.000 claims description 45
- 239000011521 glass Substances 0.000 claims description 38
- 239000011148 porous material Substances 0.000 claims description 33
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 32
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 32
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 32
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 4
- 240000007472 Leucaena leucocephala Species 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 241000206575 Chondrus crispus Species 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940096529 carboxypolymethylene Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 66
- -1 extended release Substances 0.000 abstract description 35
- 238000013268 sustained release Methods 0.000 abstract description 19
- 239000012730 sustained-release form Substances 0.000 abstract description 19
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 131
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 127
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 126
- 229950011318 cannabidiol Drugs 0.000 description 126
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 126
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 126
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 123
- 229960004242 dronabinol Drugs 0.000 description 122
- 238000004090 dissolution Methods 0.000 description 88
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- 238000000034 method Methods 0.000 description 62
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 47
- 239000007788 liquid Substances 0.000 description 47
- 239000000546 pharmaceutical excipient Substances 0.000 description 45
- 239000002904 solvent Substances 0.000 description 42
- 235000011803 sesame oil Nutrition 0.000 description 41
- 239000008159 sesame oil Substances 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000006185 dispersion Substances 0.000 description 32
- 229920000136 polysorbate Polymers 0.000 description 30
- 239000012738 dissolution medium Substances 0.000 description 29
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 29
- 229960003912 probucol Drugs 0.000 description 29
- 238000009826 distribution Methods 0.000 description 25
- 238000002156 mixing Methods 0.000 description 23
- 229920001983 poloxamer Polymers 0.000 description 22
- 239000008188 pellet Substances 0.000 description 20
- 239000003995 emulsifying agent Substances 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- 239000002775 capsule Substances 0.000 description 18
- 238000011068 loading method Methods 0.000 description 17
- 238000007922 dissolution test Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 14
- 239000008240 homogeneous mixture Substances 0.000 description 14
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 13
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 13
- 235000010980 cellulose Nutrition 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 11
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 11
- 238000001878 scanning electron micrograph Methods 0.000 description 11
- 239000003381 stabilizer Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 240000004308 marijuana Species 0.000 description 9
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 239000000945 filler Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 230000003474 anti-emetic effect Effects 0.000 description 5
- 239000002111 antiemetic agent Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229940041750 cesamet Drugs 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005563 spheronization Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 4
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 4
- 229960001076 chlorpromazine Drugs 0.000 description 4
- 229960004170 clozapine Drugs 0.000 description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229940099262 marinol Drugs 0.000 description 4
- 229960002967 nabilone Drugs 0.000 description 4
- 238000012536 packaging technology Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 4
- 229960003111 prochlorperazine Drugs 0.000 description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 3
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 3
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 208000013200 Stress disease Diseases 0.000 description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 3
- 235000019888 Vivapur Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229940009662 edetate Drugs 0.000 description 3
- 238000009477 fluid bed granulation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960001474 meclozine Drugs 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229960000762 perphenazine Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000004621 scanning probe microscopy Methods 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229960002784 thioridazine Drugs 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003081 alcohol deterrent Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 229940124332 anorexigenic agent Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 229940075522 antidotes Drugs 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002255 antigout agent Substances 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- 229940124623 antihistamine drug Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940125684 antimigraine agent Drugs 0.000 description 2
- 239000002282 antimigraine agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 239000003200 antithyroid agent Substances 0.000 description 2
- 229940043671 antithyroid preparations Drugs 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 239000002948 appetite stimulant Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229960003564 cyclizine Drugs 0.000 description 2
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229960004993 dimenhydrinate Drugs 0.000 description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000009506 drug dissolution testing Methods 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000004083 gastrointestinal agent Substances 0.000 description 2
- 229940127227 gastrointestinal drug Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 229960003210 hyoscyamine Drugs 0.000 description 2
- 229930005342 hyoscyamine Natural products 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 2
- 229960001454 nitrazepam Drugs 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000003402 opiate agonist Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000010491 poppyseed oil Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000407 respiratory system agent Substances 0.000 description 2
- 229940125704 respiratory tract agent Drugs 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229960002277 tolazamide Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229960001128 triprolidine Drugs 0.000 description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- KEEKMOIRJUWKNK-CABZTGNLSA-N (2S)-2-[[2-[(4R)-4-(difluoromethyl)-2-oxo-1,3-thiazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(SC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F KEEKMOIRJUWKNK-CABZTGNLSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960004685 aloxiprin Drugs 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 1
- 229960001210 brexpiprazole Drugs 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003874 butobarbital Drugs 0.000 description 1
- STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MQRKKLAGBPVXCD-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one;hydrate Chemical compound O.[Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 MQRKKLAGBPVXCD-UHFFFAOYSA-L 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960001658 carbromal Drugs 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
- 229960005123 cariprazine Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229950009468 ciclazindol Drugs 0.000 description 1
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960003622 clotiazepam Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229950009702 darodipine Drugs 0.000 description 1
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002209 ethinamate Drugs 0.000 description 1
- GXRZIMHKGDIBEW-UHFFFAOYSA-N ethinamate Chemical compound NC(=O)OC1(C#C)CCCCC1 GXRZIMHKGDIBEW-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940117927 ethylene oxide Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960003670 flecainide acetate Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- BARDROPHSZEBKC-OITMNORJSA-N fosaprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NC(=O)N(P(O)(O)=O)N1 BARDROPHSZEBKC-OITMNORJSA-N 0.000 description 1
- 229960002891 fosaprepitant Drugs 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008382 intra-granule composition Substances 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960002623 lacosamide Drugs 0.000 description 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- CVQFAMQDTWVJSV-BAXNFHPCSA-N lisuride maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 CVQFAMQDTWVJSV-BAXNFHPCSA-N 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960004377 methysergide maleate Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 1
- 229960003300 pimavanserin Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- GGYSHFFKUHGBIK-BTJKTKAUSA-N pizotifen maleate Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 GGYSHFFKUHGBIK-BTJKTKAUSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- FIVSJYGQAIEMOC-ZGNKEGEESA-N rolapitant Chemical compound C([C@@](NC1)(CO[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2C=CC=CC=2)C[C@@]21CCC(=O)N2 FIVSJYGQAIEMOC-ZGNKEGEESA-N 0.000 description 1
- 229960001068 rolapitant Drugs 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
- 229960003014 rufinamide Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940043243 saccharin calcium Drugs 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960001897 stiripentol Drugs 0.000 description 1
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960000658 sumatriptan succinate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960002410 tiagabine hydrochloride Drugs 0.000 description 1
- YUKARLAABCGMCN-PKLMIRHRSA-N tiagabine hydrochloride Chemical compound Cl.C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C YUKARLAABCGMCN-PKLMIRHRSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 229960002835 trimipramine maleate Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Definitions
- the present invention relates to a multiparticulate drug delivery platform for the oral administration of one or more cannabinoids.
- the drug delivery system of the present invention achieves a targeted pharmacokinetic profile and provides a uniform drug distribution in the gastrointestinal tract.
- the delivery system of the present invention can be administered as capsules, tablets, sprinkles, or a stick pack for convenience in administration and handling.
- Cannabis the plant genus that includes both hemp and marijuana, possesses many medicinal and psychoactive properties that reportedly alleviate a wide range of symptoms experienced in connection with serious medical conditions, while providing safer and fewer serious side effects than most current prescription drugs.
- cannabis has been used to combat symptoms associated with cancer, anorexia, AIDS, chronic pain, muscle spasticity, glaucoma, arthritis, migraine, and many other illnesses.
- Cannabinoids are a class of diverse chemical compounds originating from the cannabis plant that act on cannabinoid receptors, which repress neurotransmitter release in the brain.
- THC cannabidiol
- CBD cannabidiol
- CBD and THC are the two most prominent cannabinoids found in Cannabis. While there are over 100 different cannabinoids so far identified in Cannabis by scientists, CBD and THC are by far the most extensively studied and best understood. CBD and THC both interact with the body's endocannabinoid system, a vital signaling system responsible for regulating a wide array of functions.
- THC is a psychotropic chemical derived from marijuana that acts on the body's cannabinoid receptors and resembles chemicals naturally produced by the body.
- THC is a psychoactive that activates the CB1 and CB2 receptors and affects perception, mood, consciousness, cognition, and behavior.
- THC has the properties of an analgesic and an appetite stimulant.
- THC has also been reported to create a state of relaxation and well-being, induce sleep, and cause a state of euphoria. These effects have been used to treat a variety of health issues, such as pain, inflammation, nausea, sleep apnea, and stress disorders. Additionally, THC has been shown to fight the side effects and symptoms of chemotherapy, multiple sclerosis, glaucoma, AIDS, and spinal injuries.
- Marinol® and Syndros® both contain dronabinol, a synthetic THC that is insoluble in water and has a pKA of 10.6.
- Marinol® is available as soft gelatin capsules in dosage strengths of 2.5 mg, 5 mg, and 10 mg, and Syndros® is available as an oral solution (5 mg/ml). Both Marinol® and Syndros® are indicated for the treatment of anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Cesamet® contains nabilone, a synthetic cannabinoid that is chemically similar to THC.
- nabilone is a white to off-white polymorphic crystalline powder. In aqueous media, the solubility of nabilone is less than 0.5 mg/L, with pH values ranging from 1.2 to 7.0.
- Cesamet® is available as a powder-filled capsule (1 mg/capsule) for oral administration and is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- the effects of Cesamet® have been reported to persist for a variable and unpredictable period of time following its oral administration; for example, adverse psychiatric reactions from using Cesamet® can persist for 48 to 72 hours following cessation of treatment.
- CBD is another potent chemical derived from marijuana that is widely inhaled by patients from smoking the hemp leaves.
- Epidiolex® an oral solution (100 mg/ml) containing plant-derived CBD for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.
- CBD is a white to pale yellow crystalline solid. It is insoluble in water and is soluble in organic solvents.
- the primary medical applications of CBD are to combat severe and chronic pain, stress, depression, anxiety, cancer, epilepsy, schizophrenia, multiple sclerosis, migraine, arthritis, and the adverse effects of chemotherapy.
- THC activates the cannabinoid receptors CB1 and CB2 that are present in the brain and that are responsible for THC's psychoactive effects, while CBD suppresses the CB1 and CB2 receptors by operating as an indirect antagonist of cannabinoid agonists.
- CBD suppresses the activation of the CB1 and CB2 receptors by a cannabinoid like THC, creating a balanced effect.
- THC and CBD When used in combination, THC and CBD have anti-inflammatory, appetite stimulant, antiemetic, anticonvulsant, antioxidant, neuroprotective, and antitumoral actions. THC and CBD also can be used to combat epilepsy, depression, anxiety, schizophrenia, multiple sclerosis, migraine, and arthritis; and to alleviate the symptoms of cancer, AIDS, and spinal injuries; all of which improves quality of life for patients suffering from those debilitating conditions.
- the present invention relates to a dosage form of THC and CBD, either individually or combined, that can be combined with other active agents for treatment of multiple clinical conditions.
- the present invention provides multiparticulate solid oral dosage forms comprising two or more active agents, wherein the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the drug loaded system may comprise particles (e.g., granules, particle agglomerates of any shape, beads, or pellets) having a size that may range from about 30 ⁇ m to about 1500 ⁇ m, or about 50 ⁇ m to about 1000 ⁇ m, in diameter, and with uniform loading.
- the multiparticulate solid oral dosage forms of the present invention may be formulated in a manner to provide immediate, extended, or sustained release of the two or more active agents.
- the dosage forms of the present invention also may be formulated to achieve a targeted pharmacokinetic profile and to provide uniform distribution in the gastrointestinal tract.
- the multiparticulate form can provide uniform drug loading and may be compressed into tablets (regular tablets, oral-disintegrating tablets (ODT), self-disintegrated tablets, chewable tablets), filled into capsules (conventional hard gelatin capsules and easy open capsules to sprinkle) or loaded into stick packs to sprinkle over food or into water or other liquid drinks.
- tablets regular tablets, oral-disintegrating tablets (ODT), self-disintegrated tablets, chewable tablets
- capsules conventional hard gelatin capsules and easy open capsules to sprinkle
- An aspect of the current invention relates to a composition for the immediate release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the immediate release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, and one or more intra-granular excipients.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- the population of particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the one or more intra-granular excipients may comprise one or more diluents, binders, fillers, surfactants/emulsifying agents, disintegrating agents, or a combination thereof.
- the one or more intra-granular excipients may comprise one or more cellulose-derivative diluents. Examples of cellulose-derivative diluents may include lactose, isomalt, cellulose, starch, cyclodextrin, mannitol, and sorbitol.
- each particle may further comprise one or more surfactants/emulsifying agents.
- the immediate release composition may comprise a population of particles, wherein each particle comprises at least one active agent, and a porous bead core.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- the population of particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the porous bead core may comprise a mesoporous silica bead or a porous biodegradable glass bead.
- the particles may comprise a diameter of about 10 ⁇ m and 1000 ⁇ m.
- the ratio of pore volume to particle size may range from about 0.001 to about 0.8.
- Each particle may further comprise one or more surfactants/emulsifying agents.
- an aspect of the present invention relates to a composition for the extended release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more drug-releasing agents, and a porous core.
- the particles may comprise at least one active agent, one or more drug-releasing agents, a porous core, one or more solubilizers, and one or more surfactants.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the drug-releasing agent may comprise one or more gel-forming agents.
- the one or more gel-forming agents may be selected from glyceryl monooleate, glycerol monostearate, soybean oil, propylene glycol monopalmitostearate, cellulose-based gelling agents, carboxypolymethylenes, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, chitosan, natural gums such as acacia, alginates, carrageen, guar gum, or a combination thereof.
- the ratio of the one or more gel-forming agents to the one or more surfactants may be about 10:1 to about 1:10, or about 8:1 to about 1:8, or about 5:1 to about 1:5, by weight.
- the one or more solubilizers may comprise an oil, glyceride, an alcohol, or a combination thereof.
- the oil may be selected from oils that include, but not limited to, cannabis oil and sesame oil.
- the porous core may comprise a porous bead such as a mesoporous silica bead or a porous biodegradable glass bead.
- the weight ratio of pore volume to particle size may range from about 0.001 to about 0.8.
- the pores may contain the at least one active agent and the one or more drug-releasing agents.
- the pores may contain the at least one active agent, one or more solubilizers, one or more surfactants, and one or more drug-releasing agents.
- the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more drug-releasing agents, and an inert core.
- the particles may comprise at least one active agent, one or more drug-releasing agents, an inert core, one or more solubilizers, and one or more surfactants.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the one or more drug-releasing agents may comprise one or more release-controlling polymers, one or more release-accelerating polymers (pore-formers), or a combination thereof.
- the inert core may comprise an inert material selected from the group consisting of microcrystalline cellulose, celluloses, starches, saccharides, and mixtures thereof.
- the core may comprise a coating that comprises the at least one active agent and the one or more drug-releasing agents.
- the core may comprise a coating that comprises the at least one active agent, the one or more drug-releasing agents, the one or more solubilizers, and the one or more surfactants.
- the one or more solubilizers may comprise an oil, glyceride, an alcohol, or a combination thereof.
- the oil may be selected from oils that include, but not limited to, cannabis oil and sesame oil.
- An aspect of the present invention relates to a composition for the sustained release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the sustained release composition may comprise a population of particles comprising one or more of the particles of the immediate release composition of the present invention, and one or more of the particles of the extended release composition of the present invention.
- the one or more cannabinoids may comprise THC, CBD, or a combination thereof.
- the one or more non-cannabinoid therapeutic agents may comprise one or more alcohol deterrents, analgesics and/or anti-inflammatory agents; antipyretics, anorexigenic agents and respiratory and central nervous system (CNS) stimulants, antiarrhythmic agents, anticholinergic agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheal agents, antidotes, antiemetics, antigout agents, antihistamine drugs, anti-infective agents, antimigraine agents, antineoplastic agents, antiparkinsonian agents, antipsychotics, antitussives, antiulcer agents and acid suppressants, antivirals, anxiolytics such as sedatives and/or hypnotics, atypical antipsychotics, corticosteroids, gastrointestinal drugs, hypotensive agents, immunosuppressive agents, miscellaneous therapeutic agents, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs)
- the immediate release, extended release, or sustained release compositions of the present invention may be provided in a dosage form such as a tablet (for example, an ODT, self-disintegrated tablet, or chewable tablet), capsule, or stick pack for oral administration.
- a dosage form such as a tablet (for example, an ODT, self-disintegrated tablet, or chewable tablet), capsule, or stick pack for oral administration.
- the method of preparing an immediate release composition of particles may comprise combining the at least one active agent with the one or more intra-granular excipients, and granulating the combination to produce immediate release particles.
- the method of preparing an immediate release composition of particles may comprise loading the at least one active agent onto porous bead cores.
- the method of preparing the immediate release compositions of the invention comprises preparing immediate release particles comprising at least one cannabinoid and preparing immediate release particles comprising at least one non-cannabinoid therapeutic agent, and then combining these particles into one population for the immediate release composition.
- a combination may occur, for example, by granulating particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent into one granulation.
- such a combination may occur, by mixing a population of particles comprising the at least one cannabinoid and a population of particles comprising the at least one non-cannabinoid therapeutic agent.
- the method of preparing an extended release composition of particles may comprise mixing the at least one active agent in one or more solubilizers along with one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) and loading the mixture onto porous cores.
- the method of preparing an extended release composition of particles may comprise dispersing the at least one active agent in one or more solubilizers (such as an ethanol and water mixture) along with one or more release-controlling polymers and/or one or more release-accelerating polymers (and optionally one or more stabilizing agents), and the drug dispersion may then be applied onto inert cores.
- solubilizers such as an ethanol and water mixture
- release-controlling polymers and/or one or more release-accelerating polymers and optionally one or more stabilizing agents
- the method of preparing the extended release compositions of the invention comprises preparing extended release particles comprising the at least one cannabinoid and preparing extended release particles comprising the at least one non-cannabinoid therapeutic agent, and then combining these particles into one population for the extended release composition.
- Yet another aspect of the present invention relates to methods of preparing the sustained release compositions of the invention.
- the methods may comprise mixing particles of the immediate release compositions of the invention with particles of the extended release compositions of the invention.
- an aspect of the present invention relates to methods of treating a health issue in a subject in need thereof, wherein the methods comprise administering the immediate release composition of the invention, the extended release composition of the invention, or the sustained release composition of the invention.
- the health issue may be selected from the group consisting of pain, nausea, sleep apnea, stress disorders, inflammation, depression, anxiety, epilepsy, schizophrenia, migraines, arthritis, weight loss, poor appetite, and a combination thereof.
- the composition may be administered orally.
- prior to administration the composition may be sprinkled on food or nutrient that is solid, semi-solid, or liquid; into water; or into other types of liquid drink.
- FIGS. 1A and 1B shows particle size distribution using dynamic light scattering technique (Malvern Instruments, USA) for: plain Neusilin US2 beads ( FIG. 1A ) and Neusilin US2 beads loaded with probucol in sesame oil and surfactant ( FIG. 1B ).
- FIGS. 2A and 2B shows scanning electron microscopic (SEM) images of plain Neusilin US2 beads ( FIG. 2A ) and Neusilin US2 beads loaded with probucol in sesame oil and surfactant ( FIG. 2B ).
- FIG. 3 shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention, as described in Example 1.
- FIGS. 4A and 4B shows scanning electron microscopic (SEM) images at magnifications of 30 ⁇ ( FIG. 4A ) and 75 ⁇ ( FIG. 4B ) of THC particles and CBD particles according to embodiments of the invention, as described in Example 1.
- FIG. 5 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 1.
- FIG. 6 shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention, as described in Example 2.
- FIGS. 7A and 7B shows SEM images at magnifications of 30 ⁇ ( FIG. 7A ) and 75 ⁇ ( FIG. 7B ) of THC particles and CBD particles according to embodiments of the invention, as described in Example 2.
- FIG. 8 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 3.
- FIG. 9A shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention
- FIG. 9B shows the particle size distribution of blank porous bead cores, as described in Example 3.
- FIGS. 10A-10F shows SEM images of THC and CBD particles and blank porous bead cores particles according to embodiments of the invention, as described in Example 3.
- FIGS. 10A-10C shows SEM images of THC and CBD particles at magnifications of 190 ⁇ ( FIG. 10A ), 1600 ⁇ ( FIG. 10B ), and 2200 ⁇ ( FIG. 10C ).
- FIGS. 10D-10F shows blank porous bead cores at magnifications of 220 ⁇ ( FIG. 10D ), 1000 ⁇ ( FIG. 10E ), and 1600 ⁇ ( FIG. 10F ).
- FIG. 11 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 3.
- FIGS. 12A and 12B show the dissolution profile of IR Reference Compositions A-C ( FIG. 12A ) and the dissolution profile of extended release Example Compositions A-C according to embodiments of the invention ( FIG. 12B ), as described in Example 4.
- FIG. 13 shows the dissolution profiles of extended release Example Compositions D-H according to embodiments of the invention, as described in Example 5.
- FIGS. 14A and 14B show the dissolution profile of immediate release Reference Composition D ( FIG. 14A ) and the dissolution profile of extended release Example Composition I according to embodiments of the invention ( FIG. 14B ), as described in Example 6.
- FIGS. 15A and 15B show the dissolution profile of immediate release Reference Composition E ( FIG. 15A ) and the dissolution profile of extended release Example Composition J according to embodiments of the invention ( FIG. 15B ), as described in Example 7.
- FIGS. 16A and 16B show the dissolution profile of immediate release Reference Composition F ( FIG. 16A ) and the dissolution profile of extended release Example Composition K according to embodiments of the invention ( FIG. 16B ), as described in Example 8.
- FIGS. 17A-17F shows SEM images of plain Neusilin US2 beads at magnifications of 220 ⁇ ( FIG. 17A ), 1000 ⁇ ( FIG. 17B ), and 1600 ⁇ ( FIG. 17C ); and of Neusilin US2 beads loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 190 ⁇ ( FIG. 17D ), 1600 ⁇ ( FIG. 17E ), and 2200 ⁇ ( FIG. 17F ).
- FIGS. 18A and 18B shows particles size distribution profiles of a composition of plain Neusilin US2 beads ( FIG. 18A ) and a composition of Neusilin US2 beads loaded with THC and CBD in sesame oil according to embodiments of the invention ( FIG. 18B ).
- FIGS. 19A and 19B show the dissolution profile of extended release Example Composition L according to embodiments of the invention ( FIG. 19A ) and the dissolution profile of extended release Example Composition M according to embodiments of the invention ( FIG. 19B ), as described in Example 9.
- FIG. 20 shows an SEM image of a particle of extended release Example Composition L according to embodiments of the invention, as described in Example 9.
- FIGS. 21A and 21B show the dissolution profile of immediate release Reference Composition F ( FIG. 21A ) and the dissolution profile of extended release Example Composition N according to embodiments of the invention ( FIG. 21B ), as described in Example 10.
- FIGS. 22A and 22B show the dissolution profile of immediate release Reference Composition G ( FIG. 22A ) and the dissolution profile of extended release Example Composition O according to embodiments of the invention ( FIG. 22B ), as described in Example 11.
- FIGS. 23A and 23B show the dissolution profile of immediate release Reference Composition H ( FIG. 23A ) and the dissolution profile of extended release Example Composition I according to embodiments of the invention ( FIG. 23B ), as described in Example 12.
- FIGS. 24A-24F shows SEM images of plain Cellets at magnifications of 30 ⁇ ( FIG. 24A ), 120 ⁇ ( FIG. 24B ), and 250 ⁇ ( FIG. 24C ); and of Cellets loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 50 ⁇ ( FIG. 24D ), 120 ⁇ ( FIG. 24E ), and 450 ⁇ ( FIG. 24F ).
- FIGS. 25A-25F shows SEM images of plain Suglets® 40/45 at magnifications of 50 ⁇ ( FIG. 25A ), 200 ⁇ ( FIG. 25B ), and 400 ⁇ ( FIG. 25C ); and of Suglets® 40/45 loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 50 ⁇ ( FIG. 25D ), 200 ⁇ ( FIG. 25E ), and 600 ⁇ ( FIG. 25F ).
- FIGS. 26A and 26B show particle size distribution of plain Cellets ( FIG. 26A ) and Cellets loaded with CBD according to embodiments of the invention ( FIG. 26B ).
- FIGS. 27A and 27B show particle size distribution of plain Suglets® 40 / 45 ( FIG. 27A ) and Suglets® 40/45 loaded with CBD according to embodiments of the invention ( FIG. 27B ).
- multiparticulate dosage forms are provided for administering two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- a final composition may comprise the two or more active agents in an amount of about 1% to about 90% w/w, or about 5% to about 50% w/w.
- An aspect of the invention relates to immediate release, extended release, or sustained release compositions comprising a population of particles that contain the two or more active agents.
- These compositions may be provided in a dosage form such as a tablet (for example, an ODT, self-disintegrated tablet, or chewable tablet), capsule, or stick pack.
- compositions of the present invention relate to methods of preparing the compositions of the present invention, and methods of treatment involving administering the compositions of the present invention.
- compositions of the present invention comprise two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the at least one cannabinoid may comprise THC, CBD, or a combination thereof.
- the at least one non-cannabinoid therapeutic agent may be selected from active agents that can be used to help treat the various health conditions encompassed by the methods of treatment according to the present invention.
- the at least one non-cannabinoid therapeutic agent may be selected from a group consisting of alcohol deterrents, such as disulfiram, naltrexone, acamprosate, gabapentin, and topiramate; analgesics and/or anti-inflammatory agents such as aloxiprin, auranofin, azapropazone, benorylate, diflunisal, etodolac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, and su
- compositions of the present invention may be an immediate release composition, extended release composition, or a sustained release composition.
- the immediate release compositions of the present invention may comprise particles, in which each particle may comprise at least one active agent and one or more intra-granular excipients.
- the one or more intra-granular excipients may comprise one or more diluents, one or more binders, one or more fillers, one or more surfactants/emulsifying agents, one or more disintegrants, or a combination thereof.
- the immediate release compositions of the present invention may comprise particles, in which each particle may comprise at least one active agent and a porous bead core.
- the porous bead core may be a carrier for the absorption and release of liquids, e.g., silica bead.
- the core may comprise a silica bead, a biodegradable glass bead, or any other bead made of any compatible materials known in the art as suitable for oral administration (e.g., porous ceramics, porous calcium carbonate particles, porous zeolite particles, etc.).
- the core may comprise one or more pores that extend from the surface of the core.
- the core may contain the one or more cannabinoids. According to some embodiments, the ratio of pore volume to particle size of the core may be between about 0.001 to about 0.8.
- the core is selected to achieve a free flowing multiparticulate system.
- the core may comprise mesoporous silica (e.g. Syloid® XDP 3150 (Grace, USA), Davisil® LC150A (Grace, USA), Neusilin® US2 (Fuji Chemicals, Japan)).
- the at least one active agent may comprise at least one cannabinoid, at least one non-cannabinoid therapeutic agent, or a combination of at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- each particle does not comprise both at least one cannabinoid and at least one non-cannabinoid therapeutic agent
- the particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the immediate release composition of the present invention may release a particular percentage of the active agents (i.e., the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent) within a certain amount of time, as determined by dissolution testing.
- the active agents i.e., the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent
- the dissolution test may be performed under the conditions summarized in Table 1 below.
- the composition of the present invention may release about 30% or greater of the one or more cannabinoids over a period of about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test. In some embodiments, the composition may release about 50% or greater of the one or more cannabinoids over a period of about 60 minutes (1 hour) or less, or about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test.
- the composition may release about 80% or greater of the one or more cannabinoids over a period of about 90 minutes (1.5 hours) or less, or about 60 minutes (1 hour) or less, or about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test.
- the composition of the present invention may comprise particles having a particular size distribution.
- about 80% of the particles may between about 20 ⁇ m and about 2000 ⁇ m in diameter, or between about 30 ⁇ m and about 1000 ⁇ m in diameter, or between about 40 ⁇ m and about 900 ⁇ m in diameter.
- about 80% of the particles may between about 2 ⁇ m and about 500 ⁇ m in diameter, or between about 4 ⁇ m and about 300 ⁇ m in diameter, or between about 5 ⁇ m and about 200 ⁇ m in diameter.
- extended release is characterized by the gradual release of the active agents from the particles of the composition over an extended period of time, optionally greater than about 30 minutes. With extended release, the rate of release of the active agents from the particles is controlled in order to maintain therapeutic activity of the active agents for a longer period of time.
- the composition may release greater than about 40% of the one or more active agents over a period of about 6 hours or more. In certain embodiments, the composition may release the one or more active agents over a period of about 12 hours to about 24 hours.
- the term “solubilizer” refers to a solubility enhancement excipient that increases the bioavailability of the one or more active agents.
- the purpose of the one or more solubilizers is to achieve a concentrated, homogenous, and stable solution in order to deliver the one or more active agents in an efficient way.
- the one or more solubilizers for use in the present invention may include, but are not limited to, oil, glyceride, an alcohol, or a combination thereof.
- the oil may be selected from the group consisting of cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, almond oil, sesame oil, rapeseed oil, peppermint oil, poppy seed oil, canola oil, palm kernel oil, hydrogenated soybean oil, hydrogenated vegetable oil, and a combination thereof.
- the glyceride may be selected from the group consisting of a monoglyceride, diglyceride, triglyceride, and a combination thereof.
- the alcohol may be a monohydric alcohol, e.g., ethanol, methanol, or isopropyl alcohol.
- the one or more solubilizers may be a hydroalcoholic mixture.
- drug-releasing agents relates to agents that control drug delivery so that the active agents are released in a predesigned manner. As a result, the drug-releasing agents contribute to the rate and extent of the cannabinoids' active availability to the body.
- stabilizing agents may include, but are not limited to, tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, isoascorbic acid, potassium salt of sulfurous acid (e.g., potassium metabisulfite), sodium salt of sulfurous acid (e.g., sodium met abisulfite), vitamin E, lecithin, ascorbyl palmitate, edetic acid, edetate salt (e.g., EDTA), or a combination thereof.
- the stabilizing agents may be present in the composition in an amount of about 0.001% to about 5% by weight, or as suitable in order to achieve a stabilized composition.
- the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more lipid-based gel-forming agents, and a porous core.
- the particles may comprise at least one active agent, one or more lipid-based gel-forming agents, a porous core, one or more solubilizers, and one or more surfactants.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the particles may comprise one or more stabilizing agents.
- the one or more gel-forming agents may be selected from glyceryl monooleate (e.g., Capmul GMO-50; Abitec Corp., USA), glycerol monostearate (e.g., GeleolTM Mono and Diglycerides; Gattefosse, USA), glyceryl distearate, polyglyceryl-3 dioleate (Geloil®; Gattefosse, USA), soybean oil, propylene glycol monopalmitostearate (e.g., MonosteolTM; Gattefosse, USA), cellulose-based gelling agents, carboxypolymethylenes (e.g., Carbopol® or Carbomer®), hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, chitosan, natural gums (e.g., acacia, alginates, carrageen, guar gum), and a combination thereof.
- the one or more gel-forming agents may comprise glyce
- the weight ratio of the one or more gel-forming agents to the one or more surfactants may be about 10:1 to about 1:10, or about 8:1 to about 1:8, or about 5:1 to about 1:5. According to certain embodiments, the ratio of the one or more gel-forming agents to the one or more surfactants may be about 1:1.
- cellulose-based and gum-based gelling agents can be added with or without surfactants.
- the porous core may be the same as the porous bead core described above for the immediate release composition.
- the core may contain the at least one active agent, the one or more solubilizers, and the one or more gel-forming agents.
- the ratio of pore volume to particle size of the core may be between about 0.001 to about 0.8.
- the pores may be configured such that the one or more gel-forming agents are located in the pores closer to the surface of the core than the at least one active agent and the one or more solubilizers.
- the pores may be configured such that the one or more gel-forming agents are located in the pores closer to the surface of the core than the at least one active agent, the one or more solubilizers, and the one or more surfactants.
- the core is selected in consideration of loading capacity and its capability of achieving a free-flowing multiparticulate system.
- the core comprises mesoporous silica (e.g. Syloid® XDP 3150 (Grace, USA), Davisil® LC150A (Grace, USA), Neusilin® US2 (Fuji Chemicals, Japan)). Particle size, pore volume and specific surface area for the silica beads are given in Table 2 below.
- the ratio of pore volume to particle size was determined using dynamic light scattering technique and was highest for Neusilin US2 beads.
- the particle size distribution for the Neusilin US2 beads is shown in FIG. 1A having d90 as 108 ⁇ m and a bimodal distribution.
- the particle size distribution of the Neusilin US2 beads was changed to d90 of 182 ⁇ m having a unimodal distribution curve, as shown in FIG. 1B .
- Scanning electron microscopy images for both plain and loaded Neusilin US2 beads are illustrated in FIGS. 2A and 2B .
- FIG. 2A depicts plain Neusilin US2 beads
- FIG. 2B depicts Neusilin US2 beads loaded with probucol (as a surrogate active ingredient) in sesame oil and a surfactant.
- silica beads considered their flowability upon maximum drug loading. Weight ratios 2:1, 3:1, and 4:1 of probucol (as a surrogate active ingredient) in sesame oil and surfactant to silica were evaluated for the maximum drug loading capacity while retaining the free flowing capacity of the silica beads. Angle of repose of Syloid® XDP 3150 beads and Davisil® LC150A beads is between 35-40° representing passable flowability, as shown in Table 1. However, the angle of repose of Neusilin® US2 beads is 30°, shown in Table 2, which represents better flowability as compared to Syloid® XDP 3150 beads and Davisil® LC150A beads.
- Syloid® XDP 3150 beads and Davisil® LC150A beads displayed a loss in their flowability when loaded with the 2:1 weight ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica.
- Neusilin® US2 beads retained their free flowing properties at the 2:1 and 3:1 weight ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica. However, at 4:1 ratio, the flowability of Neusilin® US2 beads appeared to be reduced.
- Neusilin® US2 beads were identified as a carrier substrate with optimized drug loading of 2:1 and 3:1 wieght ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica.
- Syloid® XDP 3150 and Davisil® LC150A carrier substrates nonetheless display properties that are conducive for use as the core in the compositions of the present invention.
- one or more surfactants are used in the composition.
- surfactants are included to maximize the complete release of the one or more active agents from the pores of the cores.
- the active agents may be hydrophobic and their release upon dissolution in aqueous medium of the gastrointestinal tract is determined by various intrinsic factors such as fluid volume, peristaltic movement, concentration gradient, food effect, bile salts, and transit time. Since the loading of the one or more active agents onto porous cores is achieved by the capillary action and in consideration of the greater affinity of hydrophobic active agents to the cores, the release of the one or more active agents from the pores warrants an emulsification action.
- the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent; one or more drug-releasing agents that comprise one or more release-controlling polymers, one or more release-accelerating polymers, or a combination thereof; and an inert core.
- the particles may comprise at least one active agent; one or more drug-releasing agents that comprise one or more release-controlling polymers, one or more release-accelerating polymers, or a combination thereof; an inert core; and one or more solubilizers.
- the at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent.
- each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- the particles may comprise one or more stabilizing agents.
- the one or more release-controlling polymers may be selected from, for example, ethyl cellulose, polymethacrylate copolymers, copolymers derived from esters of acrylic and methacrylic acid (e.g., Eudragit® such as Eudragit® L-30D, Eudragit® FS-30D), polyacrylic acid-based polymers, polyacrylates, methacrylic acid co-polymers, polyvinyl acetate (e.g., Kollicoat® SR-30D), polyvinyl alcohol, and combinations thereof.
- the one or more release-accelerating polymers may be selected from polyvinylpyrrolidones or cellulose derivatives that are water soluble.
- Diffusion is defined as a process of drug transport from a region of high concentration to a region of low concentration.
- the core may comprise an inert material selected from the group consisting of microcrystalline cellulose, celluloses, starches, and saccharides; natural polymers that include, but are not limited to, chitosan, alginate, and collagen protein/polypeptides; synthetic polymer-based materials that include, but are not limited, to polylactic acid, polycaprolactone, polyglycolic acid, and polylactic-co-glycolic acid; ceramics that include, but are not limited to, calcium phosphate, hydroxyapatite, and ⁇ -tricalcium phosphate; glass that include, but are not limited to, borate-based glass, silicate-based glass, and phosphate-based glass; and combinations thereof.
- inert material selected from the group consisting of microcrystalline cellulose, celluloses, starches, and saccharides
- natural polymers that include, but are not limited to, chitosan, alginate, and collagen protein/polypeptides
- synthetic polymer-based materials that include, but are not limited
- the core may comprise a coating that comprises the one or more active agents; and the one or more release-controlling polymers, the one or more release-accelerating polymers, or a combination thereof.
- the composition of the present invention can exhibit a dissolution profile that is characteristic of extended release.
- the composition of the present invention when subjected to water as a dissolution medium, may exhibit a percent release of the one or more active agents of not more than about 20%, or not more than about 30%, or not more than about 40%, or not more than about 50% by weight, after 30 minutes; or not more than about 30%, or not more than about 40%, or not more than about 50%, or not more than about 60% by weight, after 60 minutes; or not more than about 40%, or not more than about 50%, or not more than about 60%, or not more than about 70% by weight, after 120 minutes.
- composition of the present invention may be in various dosage forms, for example, in capsules, tablets (including regular tablets, ODT, self-disintegrated tablets, chewable tablets), sachets, sprinkles, or a stick pack.
- the composition may comprise excipients such as binding agents, fillers, lubricants, disintegrants, antioxidants, wetting agents, flavors/sweeteners, or a combination thereof.
- compositions of the present invention may comprise one or more excipients.
- the immediate release composition may comprise a population of particles, in which each particle includes one or more intra-granule excipients, such as one or more diluents, one or more binders, one or more fillers, one or more surfactants/emulsifying agents, one or more disintegrating agents, or a combination thereof.
- the extended release composition may comprise a population of particles, in which each particle may comprise one or more excipients such as one or more surfactants.
- the dosage forms of the compositions may comprise one or more excipients such as one or more binding agents, fillers, surfactants, lubricants, disintegrants, antioxidants, wetting agents, or flavors/sweeteners.
- Diluents may serve different functions, such as to increase weight and improve content uniformity, improve cohesion, and/or promote flow.
- diluents include, but are not limited to, cellulose derivatives such as lactose, sucrose, isomalt, cellulose, starch, cyclodextrin, mannitol, microcrystalline cellulose, and sorbitol; calcium carbonate; plain or anhydrous calcium phosphate; calcium hydrogen phosphate dehydrate; calcium phosphate di- or tri-basic; magnesium carbonate; magnesium oxide; starch; sodium chloride; and a combination thereof.
- cellulose derivatives such as lactose, sucrose, isomalt, cellulose, starch, cyclodextrin, mannitol, microcrystalline cellulose, and sorbitol
- calcium carbonate plain or anhydrous calcium phosphate
- calcium hydrogen phosphate dehydrate calcium phosphate di- or tri-basic
- magnesium carbonate magnesium oxide
- starch sodium chloride
- Binders are excipients that may act as an adhesive to “bind together” particles and, in some cases, impart mechanical strength.
- binders can also provide volume to the composition.
- examples of binders may include, but are not limited to, sugars such as sucrose, lactose, and glucose; corn syrup; soy polysaccharide; gelatin; povidone (e.g., Kollidon®, Plasdone®); Pullulan; cellulose derivatives such as microcrystalline cellulose, hydroxypropylmethyl cellulose (e.g., Methocel), hydroxypropyl cellulose (e.g., Klucel®), ethylcellulose, hydroxyethyl cellulose, carboxymethylcellulose sodium, and methylcellulose; acrylic and methacrylic acid co-polymers; carbomer (e.g., Carbopol®); polyvinylpolypyrrolidine, polyethylene glycol (Carbowax®); pharmaceutical glaze; alginates such as alginic acid and sodium alginate;
- Fillers may increase the bulk of the composition and may make it easier to handle.
- Examples of fillers may include, but are not limited to, lactose, dextrose, saccharose, cellulose, starch, calcium phosphate, sucrose, dextrates, dextrin, maltodextrin, microcrystalline cellulose (e.g., PH102 or PH200, Avicel®), microfine cellulose, powdered cellulose, pregelatinized starch (e.g., Starch 1500®), calcium phosphate dihydrate, soy polysaccharide (e.g., Emcosoy®), gelatin, silicon dioxide, calcium sulfate, calcium carbonate, magnesium carbonate, magnesium oxide, sorbitol, mannitol, kaolin, polymethacrylates (e.g., Eudragit®), potassium chloride, sodium chloride, talc, and a combination thereof.
- lactose dextrose, saccharose, cellulose, starch, calcium phosphate,
- Disintegrants may assist in breaking up the particles when exposed to an aqueous environment.
- examples of disintegrants may include, but are not limited to, modified sodium starch glycolate, cross-linked povidone or crospovidone (e.g., Kollidon®), hydroxyl propyl cellulose, starch, alginic acid, sodium alginate, sodium carboxy-methylcellulose, croscarmellose sodium, carmellose sodium, microcrystalline cellulose, carboxystarch sodium, carboxymethyl starch sodium, potato starch, wheat starch, corn starch, rice starch, partly pregelatinized starch, hydroxypropyl starch, alginates, carbonates, and a combination thereof.
- modified sodium starch glycolate cross-linked povidone or crospovidone (e.g., Kollidon®)
- hydroxyl propyl cellulose starch
- alginic acid sodium alginate
- sodium carboxy-methylcellulose croscarmellose sodium
- carmellose sodium carmellose sodium
- Surfactants/emulsifying agents promote self-emulsification.
- surface area expansion is created between the two phases.
- the emulsion is stabilized by the surfactant/emulsifying agent molecules that form a film around the internal phase droplet.
- the excess surface free energy is dependent on the droplet size and the interfacial tension. If the emulsion is not stabilized using surfactants/emulsifying agents, the two phases will separate reducing the interfacial tension and the free energy.
- SEDDS self-emulsifying drug delivery systems
- SMDDS self-micro-emulsifying drug delivery systems
- SEDDS self-micro-emulsifying drug delivery systems
- SEDDS self-micro-emulsifying drug delivery systems
- hydrophilic solvents and co-solvents/surfactants/emulsifying agents that have the ability to form oil-in-water emulsions upon mild agitation followed by dilution in aqueous media, such as gastrointestinal fluids.
- surfactants/emulsifying agents may include, but are not limited to, sorbitan esters, ethoxylated sorbitan esters (Tween® 80; Sigma Aldrich, USA), ethoxylated linear alcohols, ethoxylated alkyl phenols, fatty acid esters, amine and amide derivatives, alkylpolyglucosides, ethyleneoxide/propylene oxide copolymers, polyalcohols and ethoxylated polyalcohols, thiols (e.g., mercaptans) and derivatives, poloxamers, polyethylene glycol-fatty acid esters, lecithins, and mixtures thereof.
- sorbitan esters ethoxylated sorbitan esters
- ethoxylated sorbitan esters Teween® 80; Sigma Aldrich, USA
- ethoxylated linear alcohols ethoxylated alkyl phenols
- fatty acid esters
- the surfactant/emulsifying agent may be selected from polysorbates (Tween® 80; Sigma Aldrich, USA), and polyethylene glycol esters of ricinoleic acid (Kolliphor® RH40, Kolliphor® EL; BASF, Germany).
- Lubricants may reduce friction between granules and thus enhance followability, as well as prevent sticking to die wall in tablet compression and facilitate powder-filling in encapsulation. Lubricants may also assist with disintegration time and impact dissolution rate.
- examples of lubricants may include, but are not limited to, calcium stearate, castor oil hydrogenated, glyceryl monostearate, glyceryl behenate, magnesium stearate, mineral oil, polyethylene glycol, polaxamer 407 or 188 or plain, sodium lauryl sulfate, sodium benzoate, stearic acid, sodium stearyl fumarate, silica, talc, and a combination thereof.
- Antioxidants can have positive effects on the stability and efficacy of the composition.
- antioxidants may include, but are not limited to, acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), monothioglycerol, potassium nitrate, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfite, vitamin E or a derivative thereof, propyl gallate, edetate (EDTA) (e.g., disodium edetate), diethylenetriaminepentaacetic acid (DTPA), triglycollamate (NT), and a combination thereof.
- EDTA edetate
- DTPA diethylenetriaminepentaacetic acid
- NT triglycollamate
- Antioxidants may also comprise amino acids such as methionine, histidine, cysteine and those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid.
- Any stereoisomer e.g., L-, D-, or a combination thereof
- any particular amino acid e.g., methionine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and combinations thereof
- these stereoisomers may be present so long as the amino acid is present either in its free base form or its salt form.
- the L-stereoisomer may be used.
- Flavors/sweeteners can help make the composition more palatable.
- flavors/sweeteners may include, but are not limited to, sugar, dextrose, fructose, aspartame, glycerin, mannitol, sucrose, saccharin sodium, acesulfame potassium, dextrates, liquid glucose, maltitol, saccharin, saccharin calcium; saccharin sodium, sodium cyclamate, sorbitol, stevia, syrup, xylitol, and a combination thereof.
- sustained release is characterized by the continuous release of the active agents from the particles of the composition over a prolonged period of time, optionally greater than about 60 minutes.
- the sustained release composition may comprise a population of particles comprising one or more of the particles of the immediate release composition of the present invention, and one or more of the particles of the extended release composition of the present invention.
- the amounts of the particles of the immediate release composition and the particles of the extended release composition may be based on achieving a pre-determined release profile.
- the release profile may comprise a rapid release of the active agents, followed by a more gradual release of the active agents.
- the rapid release may comprise about 30% to about 70% by weight of the total active agents, or about 40% to about 60% by weight of the total active agents, released within about 60 minutes (1 hour) or less, or about 30 minutes or less, or about 15 minutes or less.
- the gradual release may comprise the remaining about 30% to about 70% by weight of the total active agents, or the remaining about 40% to about 60% by weight of the total active agents, released after about 60 minutes (1 hour), or after about 120 minutes (2 hours), or after about 180 minutes (3 hours), or after about 240 minutes (4 hours).
- the release of the active agents may be prolonged up to 1440 minutes (24 hours), as intended for the therapeutic effect.
- methods of preparing immediate release compositions of the present invention may comprise (a) combining the at least one active agent with one or more intra-granular excipients, and granulating the combination to produce immediate release particles; or (b) loading the at least one active agent onto porous bead cores to produce immediate release particles.
- the at least one active agent used in the methods above may comprise at least one cannabinoid, or at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the methods may comprise preparing immediate release particles that comprises the at least one cannabinoid as the at least one active agent, preparing immediate release particles that comprises the at least one non-cannabinoid therapeutic agent as the at least one active agent, and then combining the immediate release particles comprising at least one cannabinoid and the immediate release particles comprising the at least one non-cannabinoid therapeutic agent to form the immediate release composition.
- Such a combination may occur, for example, by granulating particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent into one granulation.
- such a combination may occur, by mixing a population of particles comprising the at least one cannabinoid and a population of particles comprising the at least one non-cannabinoid therapeutic agent.
- the at least one active agent that is combined with the one or more intra-granular excipients or that is loaded onto porous bead cores may be in a granulating liquid.
- the granulating liquid may be an emulsion, suspension, hydroalcoholic mixture, or a combination thereof.
- the granulating liquid may comprise one or more solubilizing agents.
- the one or more solubilizing agents may be an oil, a glyceride, an alcohol, a hydroalcoholic solution, or a combination thereof.
- Examples of an oil may include, but are not limited to, sesame oil, cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, almond oil, rapeseed oil, peppermint oil, poppy seed oil, canola oil, palm kernel oil, hydrogenated soybean oil, hydrogenated vegetable oil, and a combination thereof.
- Examples of a glyceride may include, but are not limited to, a monoglyceride, diglyceride, triglyceride, and a combination thereof.
- Examples of an alcohol may include, but are not limited to, a monohydric alcohol, e.g., ethanol, methanol, or isopropyl alcohol.
- Examples of a hydroalcoholic mixture may include, but are not limited to, isopropyl alcohol mixed with water, or ethanol mixed with water, in varying ratios.
- the granulating liquid may further comprise one or more surfactants/emulsifying agents.
- the methods of the invention further comprise preparing the granulating liquid comprising the at least one active agent.
- Preparation of the granulating liquid may involve mixing the at least one active agent with the one or more solubilizing agents until the at least one active agent is dissolved.
- preparation of the granulating liquid may comprise mixing other components, such as one or more surfactants/emulsifying agents, with the at least one active agent and the one or more solubilizing agents.
- the mixing of the contents may be by methods known in the art. For example, the contents may be mixed by simple mixing, or may be mixed with a mixing device continuously, periodically, or a combination thereof. Examples of mixing devices may include, but are not limited to, a magnetic stirrer, shaker, a paddle mixer, homogenizer, and any combination thereof.
- the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent may be in the same granulating liquid, or may be in different granulating liquid.
- the THC and CBD may be in the same granulating liquid, or may be in different granulating liquids.
- the granulating liquid may be combined with one or more intra-granular excipients, and the combination may be granulated to produce immediate release particles.
- the combination of the granulating liquid may occur before granulation, or may occur concurrently in whole or in part with granulation.
- the granulating liquid may be combined together before combining with the one or more intra-granular excipients.
- the granulating liquid may be combined together simultaneously with combining with the one or more intra-granular excipients.
- the granulating liquids may be combined together before combining with the one or more intra-granular excipients.
- the granulating liquids may be combined together simultaneously with combining with the one or more intra-granular excipients.
- the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a fluid bed granulation process.
- the one or more intra-granular excipients may be loaded into a granulator bowl of a fluid bed granulator and fluidized.
- the granulating liquid(s) may be added into the granulator bowl and onto the one or more intra-granular excipients.
- the addition of the granulating liquid(s) may be via a top spray, bottom spray, tangential spray, or an equivalent thereof.
- the parameters of this process including the amount of pressure necessary to fluidize the one or more excipients in the granulator bowl, the inlet air temperature in the granulator bowl, the humidity level in the granulator bowl, the spray rate of the granulating liquid(s), and the fluid bed spray nozzle size and height, can all be determined by one of ordinary skill in the art.
- Examples of fluid bed granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, Sainty International Group, GEA Group, Senieer, LB Bohle, Robert Bosch Packaging Technology GmbH, and SPX FLOW Danmark.
- the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a wet granulation process.
- the wet granulation process may be performed with a high-shear granulator.
- the one or more intra-granular excipients may be loaded into a bowl of a high-shear granulator and mixed at speeds ranging from about 25 rpm to about 1000 rpm, or about 100 rpm to about 500 rpm.
- the granulating liquid(s) may be added into the granulator bowl and onto the one or more intra-granular excipients, and the combination of the granulating liquid(s) and the one or more excipients is mixed under high shear at speeds ranging from about 500 rpm to about 5000 rpm, or about 1000 rpm to about 3000 rpm.
- the parameters of this process, such as the addition rate of the granulating liquid(s) can all be determined by one of ordinary skill in the art.
- the high-shear granulator may be a vertical high-shear granulator.
- the vertical high-shear granulator may be top-driven or bottom-driven.
- the high-shear granulator may be a horizontal high-shear granulator.
- high-shear granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, SERVOLiFT LLC, Sainty International Group, GEA Group, Senieer, LB Bohle, and Robert Bosch Packaging Technology GmbH.
- the wet granulation process may be performed with the Glatt CPS' technology (Complex Perfect Spheres Technology).
- CPSTM is a patented technology by Glatt GMBH in which spherical granules are manufactured in two phases (i) nucleation of powders in which the solvent acts as a binder to create bridges between the particles of the active ingredient and a filler (e.g., microcrystalline cellulose), resulting in agglomeration; and (ii) spheronization of the granules due to centrifugal force exerted by the simultaneous spinning of the modified rotor disc to produce the smooth spherical granules/pellets.
- the CPS technology is disclosed in U.S. Pat.
- the one or more intra-granular excipients may be loaded into a bowl and the granulating liquid(s) may be added into the bowl and onto the one or more excipients.
- the wet granulation process may be performed by extrusion-spheronization.
- the one or more intra-granular excipients may be loaded into a bowl and the granulating liquid(s) may be added into the bowl and onto the one or more intra-granular excipients.
- the combination of the granulating liquid(s) and the one or more excipients may be mixed, such as with a planetary mixer, a high-shear mixer as described above, or a sigma blade mixer.
- the combination mixture may then undergo extrusion, in which pressure is applied to the combination mixture until it flows out through one or more orifices to produce the extrudates.
- Extrusion may be performed using a screw extruder, which uses a screw to develop the necessary pressure to force the combination mixture to flow through the one or more orifices; sieve extruder, which uses a rotating or oscillating arm to press the combination mixture through a sieve; basket extruder, which uses a rotating or oscillating arm to press the combination mixture through a sieve that is part of a vertical cylindrical wall; roll extruder, in which the combination mixture is fed between a roller and a perforated plate or ring due; ram extruder, in which the combination mixture compressed and forced through one or more orifices by a piston that is inside a cylinder or channel; or other types of extruders known in the art.
- the extruded combination mixture may then undergo spheronization, in which the mixture is broken into uniform lengths and are gradually transformed into spherical shapes.
- the parameters of the extrusion-spheronization process can be determined by one of ordinary skill in the art.
- Examples of extrusion-spheronization equipment that may be used in these methods of the invention may include those manufactured by Glatt GMBH, Sainty International Group, GEA Group, LB Bohle, and Robert Bosch Packaging Technology GmbH.
- the wet granulation process may be performed with a connection mixer, roller compactor, or “V” blender, using methods known in the art.
- the particles may be dried using methods known in the art, for example, using a fluid bed processor.
- the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a spray granulation process.
- the granulating liquid(s), which includes one or more surfactants as described above, is mixed well with the one or more intra-granular excipients, resulting in a dispersion.
- This dispersion may comprise about 5% to about 90% of solid content.
- the dispersion is then sprayed onto a fluidized or spouted bed to produce particles.
- the parameters of this process can be determined by one of ordinary skill in the art. Examples of spray granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, GEA Group, LB Bohle, Robert Bosch Packaging Technology GmbH, and Allgaier Werke GmbH.
- the spray granulation process may be performed using Procell® sprouted bed technology.
- the Procell technology is disclosed in U.S. Pat. Nos. 7,993,595 and 8,597,685, and in European Patent Nos. 1125629 and 1325775, which are all incorporated herein by reference.
- the granulating liquid(s) comprising the at least one active agent may be loaded onto porous bead cores.
- the granulating liquid(s) may be loaded onto the porous bead cores by mixing the granulating liquid(s) with the cores.
- a high shear granulator may be used to mix the granulating liquid(s) with the porous bead cores.
- the mixing may occur until a free-flowing powder mixture is produced. Thereafter, a composition according to the present invention is formed.
- the particles comprising the at least one active agent prepared by the methods described above may be sized, milled, and screened according to methods known in the art.
- the particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies.
- Particles comprising different active agents may be combined prior to processing them into the dosage form.
- methods of preparing extended release compositions of the present invention may comprise (a) mixing the at least one active agent in one or more solubilizers along with one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) and loading the mixture onto a porous core; or (b) dispersing the at least one active agent in one or more solubilizers along with one or more release-controlling polymers and/or one or more release-accelerating polymers (and optionally one or more stabilizing agents), and the drug dispersion may then be applied onto inert cores (such as microcrystalline cellets or sugar spheres).
- inert cores such as microcrystalline cellets or sugar spheres
- the at least one active agent used in the methods above may comprise at least one cannabinoid, or at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent.
- the methods may comprise preparing extended release particles that comprises the at least one cannabinoid as the at least one active agent, preparing extended release particles that comprises the at least one non-cannabinoid therapeutic agent as the at least one active agent, and then combining the extended release particles comprising at least one cannabinoid and the extended release particles comprising the at least one non-cannabinoid therapeutic agent to form the extended release composition.
- the methods comprise mixing the at least one active agent and the one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) in one or more solubilizers using, for example, a sonicator and/or a vortex mixer.
- These components may be mixed in the solubilizer(s) in any order (e.g., first mixing the at least one active agent in the one or more solubilizers and then adding the one or more gel-forming agents and in some embodiments the one or more surfactants, or first mixing one or more surfactants in the one or more solubilizers and then adding the at least one active agent and the one or more gel-forming agents, or adding and mixing each component simultaneously together, etc.).
- any order e.g., first mixing the at least one active agent in the one or more solubilizers and then adding the one or more gel-forming agents and in some embodiments the one or more surfactants, or first mixing one or more surfactants in the one or more solubilizers and then adding the at least one active agent and the one or more gel-forming agents, or adding and mixing each component simultaneously together, etc.
- the at least one active agent and the one or more solubilizers may be mixed with a sonicator until uniform, and then the one or more surfactants (in some embodiments) and the one or more gel-forming agents (and optionally one or more stabilizing agents) may be added and mixed using a vortex mixer.
- the mixture may then be loaded onto the porous cores by mixing the mixture with the cores.
- a high shear granulator may be used to mix the at least one active agents/one or more gel-forming agents/other components mixture with the porous cores. Thereafter, a composition according to the present invention is formed.
- the methods comprise mixing the at least one active agent in the one or more solubilizers to form a homogenous dispersion.
- the one or more release-controlling polymers and/or the one or more release-accelerating polymers) (and optionally one or more stabilizing agents) may be then mixed with the dispersion using, for example, a vortex mixer, until a homogenous mixture is formed.
- the mixture may be then loaded onto the cores.
- the mixture may be sprayed onto the cores using, for instance, a fluid bed processor.
- the particle size and size distribution of the cores can be narrowed/adjusted to achieve uniform drug distribution and targeted delivery profile.
- the particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies. Particles comprising different active agents may be combined prior to processing them into the dosage form.
- methods of preparing sustained release compositions of the present invention may comprise mixing particles of the immediate release compositions of the invention with particles of the extended release compositions of the invention.
- the amount of the particles of the immediate release compositions and the amount of the particles of the extended release compositions may be based on achieving a pre-determined release profile.
- the particles may be mixed by simple mixing, or may be mixed with a mixing device continuously, periodically, or a combination thereof.
- mixing devices may include, but are not limited to, a magnetic stirrer, shaker, a paddle mixer, homogenizer, and any combination thereof.
- the particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies. Particles comprising different active agents may be combined prior to processing them into the dosage form.
- An aspect of the invention relates to methods of treating a health issue in a subject in need thereof, wherein the methods comprise administering an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention.
- the present invention also relates to the use of an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention for treating a health issue in a subject in need thereof.
- the use may comprise administering the composition to the subject.
- the present invention relates to the use of an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention in the manufacture of a medicament for treating a health issue in a subject in need thereof.
- the present invention further relates to an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention for use in treating a health issue in a subject in need thereof.
- the use may comprise administering the composition to the subject.
- the health issue may be selected from the group consisting of pain, nausea, sleep apnea, stress disorders, inflammation, depression, anxiety, epilepsy, schizophrenia, migraines, arthritis, weight loss, poor appetite, and combinations thereof.
- the composition may be administered orally.
- the composition prior to administration, may be sprinkled on food or nutrient that is solid, semi-solid, or liquid; into water; or into other types of liquid drink.
- composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 3 below.
- the particles were prepared using the top spray fluid bed granulation process according to embodiments of the invention.
- Example 1 % of Total Component Function Weight Granulating THC Active in 5.54 liquid (20% Dronabinol in solubilizing agent Ethanol) Kolliphor ® EL Surfactant/ 0.2 emulsifying agent Granulating CBD Active 11.08 liquid Sesame oil Solubilizing agent 8.6 Polysorbate 80 Surfactant/ 6 emulsifying agent Intra-granular Pharmatose ® Diluent 45.28 Excipient 200M (EU) (Milled Lactose Monohydrate) Kollidon ® 30 Binder 3 Vivapur ® 101 Disintegrant 20.3 (Microcrystalline Cellulose) Granulation Methanol Processing solvent Non-residual Process Purified water Processing solvent Non-residual TOTAL 100
- the particle size distribution of the composition shown in FIG. 3 , was obtained using dynamic light scattering technique (Malvern Instruments, USA). As shown in the figure, over 70% of the particles are between about 100 ⁇ m and about 700 ⁇ m in diameter.
- FIGS. 4A and 4B SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in FIGS. 4A and 4B .
- a dissolution test was performed using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the resulting dissolution profiles for both the THC particles and the CBD particles are shown in FIG. 5 . Dissolution of both the THC particles and CBD particles exhibited an immediate release dissolution profile.
- composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 4 below.
- the particles were prepared using the high-shear granulation process with the CPS technology according to embodiments of the invention.
- Example 2 Composition of Example 2. % of Total Component Function Weight Granulating THC Active in 5.54 liquid (20% Dronabinol solubilizing agent in Ethanol) Kolliphor ® EL Surfactant/ 0.2 emulsifying agent Granulating CBD Active 11.08 liquid Sesame oil Solubilizing agent 8.6 Polysorbate 80 Surfactant/ 6 emulsifying agent Intra-granular Pharmatose ® Diluent 45.28 Excipient 200M (EU) (Milled Lactose Monohydrate) Kollidon ® 30 Binder 3 Vivapur ® 101 Disintegrant 20.3 (Microcrystalline Cellulose) Granulation Methanol Processing solvent Non-residual Process Purified water Processing solvent Non-residual TOTAL 100
- the particle size distribution of the composition shown in FIG. 6 , was obtained using dynamic light scattering technique (Malvern Instruments, USA). As shown in the figure, over 70% of the particles are between about 80 ⁇ m and about 700 ⁇ m in diameter.
- FIGS. 7A and 7B SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in FIGS. 7A and 7B .
- a dissolution test was performed using 1% polysorbate 80 in distilled water as the dissolution medium in a dissolution volume of 500 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 100 rpm.
- the bath temperature was 37° C.
- composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 5 below.
- the particles were prepared by loading the THC and CBD onto porous bead cores according to embodiments of the invention.
- Example 3 Composition of Example 3. % of Component Function Total Weight THC in sesame oil Active in solubilizing agent 14 CBD Active 1.4 Tween ® 80 Surfactant/emulsifying agent 51.6 Neusilin ® US2 (Silica) Porous bead core 33 Total 100
- Particle size distribution was obtained using dynamic light scattering technique (Malvern Instruments, USA) for the composition as well as for blank porous bead cores. As shown in FIGS. 9A and 9B , over 70% of the particles of the composition are between about 20 ⁇ m and about 200 ⁇ m in diameter ( FIG. 9A ), while over 70% of the particles of the blank porous bead cores are between about 2 ⁇ m and about 100 ⁇ m in diameter ( FIG. 9B ).
- FIGS. 10A-10F SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in FIGS. 10A-10F .
- a dissolution test was performed using 1% polysorbate 80 in distilled water as the dissolution medium in a dissolution volume of 500 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 100 rpm.
- the bath temperature was 37° C.
- the resulting dissolution profiles for both the THC particles and the CBD particles are shown in FIG. 11 .
- the dissolution profile of the THC particles was nearly the same as the dissolution profile of the CBD particles, and both particles achieved 80% release in less than 20 minutes.
- Example Compositions A-C A study was performed to assess immediate release compositions (Reference Composition A-C) and extended release compositions (Example Compositions A-C) that comprise different surfactants. This study examined the dissolution profile of the compositions in order to assess the emulsification capacity of each surfactant, and to evaluate the drug-releasing agent in the extended release compositions.
- the immediate release compositions are particles comprising a porous silica bead core; a surrogate active ingredient, probucol; and a surfactant selected from Tween® 80 (Reference Composition A), Kolliphor® RH40 (Reference Composition B), or Kolliphor® EL (Reference Composition C).
- Table 6 provides a summary of these compositions, including the quantity of each component.
- the weight ratio of sesame oil to surfactant was 1:5 in each immediate release composition.
- the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant was added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug-loaded beads.
- Reference Reference Reference Component Composition A Composition B
- Composition C Probucol 1.25% 1.25% 1.25% Sesame oil 11.25% 11.25% 11.25% Surfactant 62.5% 62.5% 62.5% (Tween ® 80) (Kolliphor ® RH 40) (Kolliphor ® EL) Neusilin 25% 25% 25% US2 beads TOTAL 100% 100% 100%
- the extended release compositions are particles comprising a porous silica bead core; a surrogate active ingredient, probucol; glyceryl monooleate as a gel-forming agent; and a surfactant selected from Tween® 80 in a weight ratio of 1:1 with the glyceryl monooleate (Example Composition A), Kolliphor® RH40 in a weight ratio of 11.5:1 with the glyceryl monooleate (Example Composition B), and Kolliphor® EL in a weight ratio of about 5.25:1 with the glyceryl monooleate (Example Composition C).
- Table 7 provides a summary of these compositions, including the quantity of each component.
- the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- Example Example Example Component Composition A Composition B
- Composition C Probucol 1.3% 1.25% 1.25% Sesame oil 12% 11.25% 11.25% Glyceryl 26.7% 5% 10% monooleate Surfactant 26.7% 57.5% 52.5% (Tween ® 80) (Kolliphor ® RH 40) (Kolliphor ® EL) Neusilin 33.3% 25% 25% US2 beads TOTAL 100% 100% 100%
- a dissolution test was conducted on the compositions using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- each immediate release Reference Compositions A-C are provided in Table 8 and in FIG. 12A .
- Surfactant Tween® 80 was able to facilitate over 80% w/w release of probucol from the Neusilin® in the dissolution medium within 15 minutes as shown in Table 8.
- Surfactants Kolliphor® RH 40 and Kolliphor® EL were both able to facilitate over 80% w/w release of Probucol in sesame oil from the Neusilin® silica pores in the dissolution medium within 5 minutes, as shown in Table 8.
- FIG. 12A illustrates that all the surfactants evaluated attributed greater than 80% w/w drug release in the dissolution medium.
- Kolliphor® EL demonstrated the highest emulsification capacity yielding a release after 24 hours of 100% w/w drug from the silica pores as compared to 85% w/w with Kolliphor® RH40 and 88% w/w with Tween® 80.
- Example Composition A-C The dissolution profiles of each extended release Example Composition A-C are provided in Table 9 and in FIG. 12B .
- Example Composition B in which Kolliphor® RH40 was used as the surfactant, showed over 80% w/w drug release by 5 minutes (see Table 9 and FIG. 12B ).
- dissolution profile of Example Composition C which used Kolliphor® EL as the surfactant, showed 79% w/w drug release by 5 minutes and over 80% w/w drug release by 15 minutes (see Table 9 and FIG. 12B ).
- Example Compositions A-C TABLE 9 Dissolution profile of Example Compositions A-C. % Drug Release of Probucol Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min Example 11 15 19 27 33 42 48 50 50 Composition A Example 84 87 87 88 89 89 90 90 90 Composition B Example 79 84 85 87 87 88 88 89 89 Composition C These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of providing an extended release profile. In addition, it is hypothesized that the hydrophilicity of glyceryl monooleate may have increased the emulsification action of the beads leading to higher drug release in dissolution medium.
- compositions D-H of particles comprising a porous silica bead core; a surrogate active ingredient, probucol; glyceryl monooleate as a gel-forming agent; and a surfactant Kolliphor® EL at varying ratios with the glyceryl monooleate.
- Table 10 provides a summary of these compositions, including the quantity of each component
- the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- Kolliphor® EL and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- a dissolution test was conducted on XR Example Compositions D-H using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 11 and FIG. 13 .
- the dissolution profiles of XR Example Compositions D-F showed that 90% w/w or greater drug release within 5 minutes, which indicates that no extended release was achieved.
- the dissolution profile of XR Example Composition G exhibited 70% w/w drug release within 5 minutes, but release remained below 80% w/w through 24 hours.
- the dissolution profile of XR Example Composition H showed 50% w/w drug release at 5 minutes, which climbed to 80% w/w by 120 minutes.
- the THC was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- Example Composition I To prepare the XR Example Composition I, the THC was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- a dissolution test was conducted on IR Reference Composition D and XR Example Composition I using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 13 and FIGS. 14A and 14B .
- the dissolution profile of IR Reference Composition D showed 80% w/w THC release after 5 minutes, and about 100% w/w THC release by 12 hours (see Table 13 and FIG. 14A ).
- the dissolution profile of XR Example Composition I showed less than 20% w/w THC release after 5 minutes, and less than 60% w/w drug release after 12 hours (see Table 13 and FIG. 14B ).
- the CBD was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin US2 silica beads using a high shear granulator.
- the CBD was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- a dissolution test was conducted on IR Reference Composition E and XR Example Composition J using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 15 and FIGS. 15A and 15B .
- the dissolution profile of IR Reference Composition E showed over 70% w/w CBD release after 5 minutes, and over 90% w/w CBD release by 15 minutes (see Table 15 and FIG. 15A ).
- the dissolution profile of XR Example Composition J showed less than 25% w/w CBD release after 5 minutes, and less than 70% w/w CBD release after 12 hours (see Table 15 and FIG. 15B ).
- the THC and CBD were added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture.
- the surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator, and resulting particles were placed in a capsule.
- Example Composition K To prepare the XR Example Composition K, the THC and CBD were added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator, and resulting particles were placed in a capsule.
- a dissolution test was conducted on IR Reference Composition F and XR Example Composition K using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 17 (for release of THC of both compositions) and Table 18 (for release of CBD of both compositions) and in FIG. 16A (release of THC and CBD in IR Reference Composition F) and FIG. 16B (release of THC and CBD in XR Example Composition K).
- the dissolution profile of IR Reference Composition F showed, for both THC and CBD, over 60% w/w release within 30 minutes, and over 90% w/w release by 12 hours (see Tables 17 and 18, and FIG. 16A ).
- the dissolution profile of XR Example Composition K showed, for both THC and CBD, less than 5% w/w release after 30 minutes, and less than 60% w/w release after 12 hours (see Tables 17 and 18, and FIG. 16B ).
- FIGS. 17A-17C and FIGS. 17D-17E compare the physical appearance of plain Neusilin US2 silica beads and of the particles of IR Reference Composition F, respectively.
- the particles loaded with THC and CBD have a more textured surface as compared to the plain Neusilin US2 silica beads.
- FIGS. 18A and 18B a comparison of the particle size distribution of the plain Neusilin US2 silica beads and the particles of IR Reference Composition F is shown in FIGS. 18A and 18B .
- the plain Neusilin US2 silica beads exhibited a wider distribution of particle sizes and fewer particles having a diameter of about 40 mm or larger, as compared to the particles of IR Reference Composition F (see FIG. 18A compared to FIG. 18B ).
- THC is added in sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
- Tween® 80 and the gel-forming agent, glyceryl monooleate is added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.
- Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1. The resultant multiparticulates are loaded into a capsule.
- CBD is added in sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
- Tween® 80 and the gel-forming agent, glyceryl monooleate is added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.
- Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1. The resultant multiparticulate composition is compressed into a tablet.
- THC and CBD are added to sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
- Tween® 80 and the gel-forming agent, glyceryl monooleate are added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.
- Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1.
- the resultant multiparticulates containing CBD and THC are filled into capsules.
- compositions L and M A study was performed to assess two different extended release compositions (XR Example Compositions L and M) of particles comprising an inert core and a coating having the following: a surrogate active ingredient, probucol; two or more release-controlling polymers; and a release-accelerating polymer. Table 19 provides a summary of these compositions, including the quantity of each component.
- the probucol was mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers (Eudragit® RS and Ethocel® E-10 in Example Composition L; Eudragit® RS, Eudragit® RL, and Ethocel® E-10 in Example Composition M) and release-accelerating polymer (Kollidon® K30) were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then applied onto Cellets® (Glatt GmBH, Germany) in a beaker and the coated pellets were dried.
- a dissolution test was conducted on XR Example Compositions L and M using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 20 and in FIGS. 19A and 19B .
- the dissolution profile of XR Example Composition L showed about 13% w/w drug release within 15 minutes and about 38% w/w drug release at 120 minutes (see Table 20 and FIG. 19A ).
- the amount of drug released achieved 66% w/w at 24 hours.
- FIG. 20 is an SEM image for the Cellets coated with probucol, the release-controlling polymer, and the release-accelerating polymer.
- the dissolution profile of XR Example Composition M showed about 25% w/w drug release within 2 hours and the extended release profile was maintained through 24 hours (see Table 20, FIG. 19B ).
- the THC was mixed with methanol in a glass beaker to form a homogenous dispersion.
- the dispersion was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- Example Composition N To prepare the XR Example Composition N, the THC was mixed with methanol in a glass beaker to form a homogenous dispersion. The Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- a dissolution test was conducted on IR Reference Composition F and XR Example Composition N using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 23 and FIGS. 21A and 21B .
- the dissolution profile of IR Reference Composition F showed nearly 70% w/w THC release after 15 minutes, and over 95% w/w THC release by 120 minutes (see Table 23 and FIG. 21A ).
- the dissolution profile of XR Example Composition N showed less than 25% w/w THC release after 15 minutes, about 60% w/w THC release after 120 minutes, and less than 75% w/w THC release after 24 hours (see Table 23 and FIG. 21B ).
- the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion.
- the dispersion was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion.
- the Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- a dissolution test was conducted on IR Reference Composition G and XR Example Composition O using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 25 and FIGS. 22A and 22B .
- the dissolution profile of IR Reference Composition G showed nearly 80% w/w CBD release after 5 minutes, and over 90% w/w CBD release by 15 minutes (see Table 25 and FIG. 22A ).
- the dissolution profile of XR Example Composition O showed less than 20% w/w CBD release through 60 minutes and less than 40% w/w CBD release after 240 minutes, although at 24 hours there was about 100% w/w CBD release (see Table 25 and FIG. 22B ).
- the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion.
- the dispersion was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- Example Composition P To prepare the XR Example Composition P, the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion.
- the Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture.
- the mixture was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- a dissolution test was conducted on IR Reference Composition H and XR Example Composition P using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml.
- a USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm.
- the bath temperature was 37° C., and a 10- ⁇ m porous filter was used to sample aliquots.
- the dissolution profiles of each composition are provided in Table 27 (for release of THC of both compositions) and Table 28 (for release of CBD of both compositions) and in FIG. 23A (release of THC and CBD in IR Reference Composition H) and FIG. 23B (release of THC and CBD in XR Example Composition P).
- the dissolution profile of IR Reference Composition H showed, for both THC and CBD, about 70% w/w or greater release within 15 minutes, and over 95% w/w release by 120 minutes (see Tables 27 and 28, and FIG. 23A ).
- the dissolution profile of XR Example Composition P showed, for both THC and CBD, less than 30% w/w release after 15 minutes, and less than 70% w/w release after 120 minutes (see Tables 27 and 28, and FIG. 23B ).
- THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto Cellets in a beaker and the coated pellets were dried.
- Suglets® 40/45 loaded with THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- FIGS. 24A-24C and FIGS. 24D-24E compare the physical appearance of plain Cellets and of Cellets coated with THC and CBD, respectively.
- the Cellets loaded with THC and CBD have the appearance of coated surface morphology as compared to the plain Cellets.
- FIGS. 25A-25C and FIGS. 25D-25E compare the physical appearance of plain Suglets® 40/45 and of Suglets® 40/45 coated with THC and CBD, respectively.
- the Suglets® 40/45 loaded with THC and CBD have the appearance of coated surface morphology as compared to the plain Suglets® 40/45.
- the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion.
- the dispersion was then applied onto Cellets in a beaker and the coated pellets were dried.
- Suglets® 40/45 loaded with CBD the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto Suglets® 40/45 in a beaker and the coated pellets were dried.
- FIGS. 26A and 26B compare the particle size distribution of the plain Cellets and the Cellets loaded with CBD. As shown in these figures, there was no notable difference in particle size distribution between the plain Cellets and the Cellets loaded with CBD.
- FIGS. 27A and 27B compare the particle size distribution of the plain Suglets® 40/45 and the Suglets® 40/45 loaded with CBD. As shown in these figures, the plain Suglets® 40/45 exhibited a slightly wider distribution of particle sizes as compared to the Suglets® 40/45 coated with CBD.
- THC is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 is added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- the multiparticulates are then filled into a No. 2 capsule.
- CBD is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- the multiparticulates are then formed into a tablet.
- THC and CBD in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- the multiparticulates are then provided in a sachet.
- THC is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- the multiparticulates are then formed into tablets.
- CBD is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- the resultant multiparticulates are then provided in a capsule, which is opened and admixed with apple sauce prior to administration.
- THC and CBD in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- CBD and the antipsychotic agent clozapine are dissolved in a hydroalcoholic solution comprising ethanol, and then mixed with Tween® 80.
- the mixture is loaded onto Neusilin® US2 (Silica) and mixed homogenously using a vortex mixer to obtain immediate release particles.
- THC and CBD in combination in sesame oil, are sprayed onto Pharmatose® 200M (EU) (Milled Lactose Monohydrate), Kollidon® 30, and Vivapur® 101 (Microcrystalline Cellulose) in a graulator bowl, and the mixture undergoes fluid bed granulation. The resulting granules are sized, milled, and screened to generate immediate release particles.
- EU Unified Lactose Monohydrate
- Kollidon® 30 Kollidon® 30
- Vivapur® 101 Microcrystalline Cellulose
- THC and CBD in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion.
- the release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer.
- the mixture is then applied onto Cellets® in a beaker and the coated pellets are dried to generate extended release particles.
- the immediate release particles and the extended release particles are then mixed together in a 50:50 ratio by weight to generate a sustained release composition.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present invention relates to a multiparticulate drug delivery platform for the oral administration of one or more cannabinoids. The drug delivery system of the present invention achieves a targeted pharmacokinetic profile and provides a uniform drug distribution in the gastrointestinal tract. The delivery system of the present invention can be administered as capsules, tablets, sprinkles, or a stick pack for convenience in administration and handling.
- Cannabis, the plant genus that includes both hemp and marijuana, possesses many medicinal and psychoactive properties that reportedly alleviate a wide range of symptoms experienced in connection with serious medical conditions, while providing safer and fewer serious side effects than most current prescription drugs. For example, cannabis has been used to combat symptoms associated with cancer, anorexia, AIDS, chronic pain, muscle spasticity, glaucoma, arthritis, migraine, and many other illnesses.
- Cannabinoids are a class of diverse chemical compounds originating from the cannabis plant that act on cannabinoid receptors, which repress neurotransmitter release in the brain. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most prominent cannabinoids found in Cannabis. While there are over 100 different cannabinoids so far identified in Cannabis by scientists, CBD and THC are by far the most extensively studied and best understood. CBD and THC both interact with the body's endocannabinoid system, a vital signaling system responsible for regulating a wide array of functions.
- THC is a psychotropic chemical derived from marijuana that acts on the body's cannabinoid receptors and resembles chemicals naturally produced by the body. THC is a psychoactive that activates the CB1 and CB2 receptors and affects perception, mood, consciousness, cognition, and behavior. In medicinal application, THC has the properties of an analgesic and an appetite stimulant. THC has also been reported to create a state of relaxation and well-being, induce sleep, and cause a state of euphoria. These effects have been used to treat a variety of health issues, such as pain, inflammation, nausea, sleep apnea, and stress disorders. Additionally, THC has been shown to fight the side effects and symptoms of chemotherapy, multiple sclerosis, glaucoma, AIDS, and spinal injuries.
- Currently, there are only three drug products approved by the Food and Drug Administration (FDA) for THC: Marinol®, Syndros®, and Cesamet®. Marinol® and Syndros® both contain dronabinol, a synthetic THC that is insoluble in water and has a pKA of 10.6. Marinol® is available as soft gelatin capsules in dosage strengths of 2.5 mg, 5 mg, and 10 mg, and Syndros® is available as an oral solution (5 mg/ml). Both Marinol® and Syndros® are indicated for the treatment of anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Cesamet® contains nabilone, a synthetic cannabinoid that is chemically similar to THC. As a raw material, nabilone is a white to off-white polymorphic crystalline powder. In aqueous media, the solubility of nabilone is less than 0.5 mg/L, with pH values ranging from 1.2 to 7.0. Cesamet® is available as a powder-filled capsule (1 mg/capsule) for oral administration and is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. However, the effects of Cesamet® have been reported to persist for a variable and unpredictable period of time following its oral administration; for example, adverse psychiatric reactions from using Cesamet® can persist for 48 to 72 hours following cessation of treatment.
- CBD is another potent chemical derived from marijuana that is widely inhaled by patients from smoking the hemp leaves. To date, the FDA has only approved Epidiolex®, an oral solution (100 mg/ml) containing plant-derived CBD for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. CBD is a white to pale yellow crystalline solid. It is insoluble in water and is soluble in organic solvents. The primary medical applications of CBD are to combat severe and chronic pain, stress, depression, anxiety, cancer, epilepsy, schizophrenia, multiple sclerosis, migraine, arthritis, and the adverse effects of chemotherapy.
- The presence of CBD can balance the agonistic activity of THC. THC activates the cannabinoid receptors CB1 and CB2 that are present in the brain and that are responsible for THC's psychoactive effects, while CBD suppresses the CB1 and CB2 receptors by operating as an indirect antagonist of cannabinoid agonists. Hence, CBD suppresses the activation of the CB1 and CB2 receptors by a cannabinoid like THC, creating a balanced effect.
- When used in combination, THC and CBD have anti-inflammatory, appetite stimulant, antiemetic, anticonvulsant, antioxidant, neuroprotective, and antitumoral actions. THC and CBD also can be used to combat epilepsy, depression, anxiety, schizophrenia, multiple sclerosis, migraine, and arthritis; and to alleviate the symptoms of cancer, AIDS, and spinal injuries; all of which improves quality of life for patients suffering from those debilitating conditions.
- Because THC and CBD can impact a variety of health conditions, treatment with THC and CBD is ideal for combining with other treatments. To this end, the present invention relates to a dosage form of THC and CBD, either individually or combined, that can be combined with other active agents for treatment of multiple clinical conditions.
- The present invention provides multiparticulate solid oral dosage forms comprising two or more active agents, wherein the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. The drug loaded system may comprise particles (e.g., granules, particle agglomerates of any shape, beads, or pellets) having a size that may range from about 30 □m to about 1500 □m, or about 50 □m to about 1000 □m, in diameter, and with uniform loading. The multiparticulate solid oral dosage forms of the present invention may be formulated in a manner to provide immediate, extended, or sustained release of the two or more active agents. The dosage forms of the present invention also may be formulated to achieve a targeted pharmacokinetic profile and to provide uniform distribution in the gastrointestinal tract.
- The multiparticulate form can provide uniform drug loading and may be compressed into tablets (regular tablets, oral-disintegrating tablets (ODT), self-disintegrated tablets, chewable tablets), filled into capsules (conventional hard gelatin capsules and easy open capsules to sprinkle) or loaded into stick packs to sprinkle over food or into water or other liquid drinks.
- An aspect of the current invention relates to a composition for the immediate release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In embodiments of the invention, the immediate release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, and one or more intra-granular excipients. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- In some embodiments, the one or more intra-granular excipients may comprise one or more diluents, binders, fillers, surfactants/emulsifying agents, disintegrating agents, or a combination thereof. In certain embodiments, the one or more intra-granular excipients may comprise one or more cellulose-derivative diluents. Examples of cellulose-derivative diluents may include lactose, isomalt, cellulose, starch, cyclodextrin, mannitol, and sorbitol.
- In some embodiments, each particle may further comprise one or more surfactants/emulsifying agents.
- In embodiments of the invention, the immediate release composition may comprise a population of particles, wherein each particle comprises at least one active agent, and a porous bead core. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- The porous bead core may comprise a mesoporous silica bead or a porous biodegradable glass bead. The particles may comprise a diameter of about 10 □m and 1000 □m. The ratio of pore volume to particle size may range from about 0.001 to about 0.8. Each particle may further comprise one or more surfactants/emulsifying agents.
- An aspect of the present invention relates to a composition for the extended release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In embodiments of the invention, the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more drug-releasing agents, and a porous core. In some embodiments, the particles may comprise at least one active agent, one or more drug-releasing agents, a porous core, one or more solubilizers, and one or more surfactants. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- In some embodiments, the drug-releasing agent may comprise one or more gel-forming agents. The one or more gel-forming agents may be selected from glyceryl monooleate, glycerol monostearate, soybean oil, propylene glycol monopalmitostearate, cellulose-based gelling agents, carboxypolymethylenes, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, chitosan, natural gums such as acacia, alginates, carrageen, guar gum, or a combination thereof. The ratio of the one or more gel-forming agents to the one or more surfactants may be about 10:1 to about 1:10, or about 8:1 to about 1:8, or about 5:1 to about 1:5, by weight.
- In some embodiments, the one or more solubilizers may comprise an oil, glyceride, an alcohol, or a combination thereof. The oil may be selected from oils that include, but not limited to, cannabis oil and sesame oil. In some embodiments, the porous core may comprise a porous bead such as a mesoporous silica bead or a porous biodegradable glass bead.
- The weight ratio of pore volume to particle size may range from about 0.001 to about 0.8. In some embodiments, the pores may contain the at least one active agent and the one or more drug-releasing agents. In certain embodiments, the pores may contain the at least one active agent, one or more solubilizers, one or more surfactants, and one or more drug-releasing agents.
- In embodiments of the invention, the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more drug-releasing agents, and an inert core. In some embodiments, the particles may comprise at least one active agent, one or more drug-releasing agents, an inert core, one or more solubilizers, and one or more surfactants. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- In some embodiments, the one or more drug-releasing agents may comprise one or more release-controlling polymers, one or more release-accelerating polymers (pore-formers), or a combination thereof. In some embodiments, the inert core may comprise an inert material selected from the group consisting of microcrystalline cellulose, celluloses, starches, saccharides, and mixtures thereof. In some embodiments, the core may comprise a coating that comprises the at least one active agent and the one or more drug-releasing agents. In certain embodiments, the core may comprise a coating that comprises the at least one active agent, the one or more drug-releasing agents, the one or more solubilizers, and the one or more surfactants.
- In some embodiments, the one or more solubilizers may comprise an oil, glyceride, an alcohol, or a combination thereof. The oil may be selected from oils that include, but not limited to, cannabis oil and sesame oil.
- An aspect of the present invention relates to a composition for the sustained release of two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In embodiments of the invention, the sustained release composition may comprise a population of particles comprising one or more of the particles of the immediate release composition of the present invention, and one or more of the particles of the extended release composition of the present invention.
- In some embodiments, the one or more cannabinoids may comprise THC, CBD, or a combination thereof.
- In some embodiments, the one or more non-cannabinoid therapeutic agents may comprise one or more alcohol deterrents, analgesics and/or anti-inflammatory agents; antipyretics, anorexigenic agents and respiratory and central nervous system (CNS) stimulants, antiarrhythmic agents, anticholinergic agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheal agents, antidotes, antiemetics, antigout agents, antihistamine drugs, anti-infective agents, antimigraine agents, antineoplastic agents, antiparkinsonian agents, antipsychotics, antitussives, antiulcer agents and acid suppressants, antivirals, anxiolytics such as sedatives and/or hypnotics, atypical antipsychotics, corticosteroids, gastrointestinal drugs, hypotensive agents, immunosuppressive agents, miscellaneous therapeutic agents, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), opiate agonists, opiate partial agonists, respiratory tract agents, skeletal muscle relaxants, thyroid and anti-thyroid agents, tricyclics and other norepinephrine-reuptake inhibitors, vitamins, wakefulness-promoting agents, or a combination thereof.
- In some embodiments, the immediate release, extended release, or sustained release compositions of the present invention may be provided in a dosage form such as a tablet (for example, an ODT, self-disintegrated tablet, or chewable tablet), capsule, or stick pack for oral administration.
- Another aspect of the present invention relates to methods of preparing the immediate release compositions of the invention. In embodiments of the invention, the method of preparing an immediate release composition of particles may comprise combining the at least one active agent with the one or more intra-granular excipients, and granulating the combination to produce immediate release particles. In embodiments of the invention, the method of preparing an immediate release composition of particles may comprise loading the at least one active agent onto porous bead cores. In embodiments in which each particle does not comprise both at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the method of preparing the immediate release compositions of the invention comprises preparing immediate release particles comprising at least one cannabinoid and preparing immediate release particles comprising at least one non-cannabinoid therapeutic agent, and then combining these particles into one population for the immediate release composition. Such a combination may occur, for example, by granulating particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent into one granulation.
- Alternatively, such a combination may occur, by mixing a population of particles comprising the at least one cannabinoid and a population of particles comprising the at least one non-cannabinoid therapeutic agent.
- Another aspect of the present invention relates to methods of preparing the extended release compositions of the invention. In embodiments of the invention, the method of preparing an extended release composition of particles may comprise mixing the at least one active agent in one or more solubilizers along with one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) and loading the mixture onto porous cores. In other embodiments of the invention, the method of preparing an extended release composition of particles may comprise dispersing the at least one active agent in one or more solubilizers (such as an ethanol and water mixture) along with one or more release-controlling polymers and/or one or more release-accelerating polymers (and optionally one or more stabilizing agents), and the drug dispersion may then be applied onto inert cores. In embodiments in which each particle does not comprise both at least one cannabinoid and at least one non-cannabinoid therapeutic agent, then the method of preparing the extended release compositions of the invention comprises preparing extended release particles comprising the at least one cannabinoid and preparing extended release particles comprising the at least one non-cannabinoid therapeutic agent, and then combining these particles into one population for the extended release composition.
- Yet another aspect of the present invention relates to methods of preparing the sustained release compositions of the invention. In embodiments of the invention, the methods may comprise mixing particles of the immediate release compositions of the invention with particles of the extended release compositions of the invention.
- Finally, an aspect of the present invention relates to methods of treating a health issue in a subject in need thereof, wherein the methods comprise administering the immediate release composition of the invention, the extended release composition of the invention, or the sustained release composition of the invention. In some embodiments, the health issue may be selected from the group consisting of pain, nausea, sleep apnea, stress disorders, inflammation, depression, anxiety, epilepsy, schizophrenia, migraines, arthritis, weight loss, poor appetite, and a combination thereof. In some embodiments, the composition may be administered orally. In certain embodiments, prior to administration, the composition may be sprinkled on food or nutrient that is solid, semi-solid, or liquid; into water; or into other types of liquid drink.
- For a better understanding of the present invention, reference is made to the following description of an exemplary embodiment thereof, and the accompanying drawing, wherein:
-
FIGS. 1A and 1B shows particle size distribution using dynamic light scattering technique (Malvern Instruments, USA) for: plain Neusilin US2 beads (FIG. 1A ) and Neusilin US2 beads loaded with probucol in sesame oil and surfactant (FIG. 1B ). -
FIGS. 2A and 2B shows scanning electron microscopic (SEM) images of plain Neusilin US2 beads (FIG. 2A ) and Neusilin US2 beads loaded with probucol in sesame oil and surfactant (FIG. 2B ). -
FIG. 3 shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention, as described in Example 1. -
FIGS. 4A and 4B shows scanning electron microscopic (SEM) images at magnifications of 30× (FIG. 4A ) and 75× (FIG. 4B ) of THC particles and CBD particles according to embodiments of the invention, as described in Example 1. -
FIG. 5 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 1. -
FIG. 6 shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention, as described in Example 2. -
FIGS. 7A and 7B shows SEM images at magnifications of 30× (FIG. 7A ) and 75× (FIG. 7B ) of THC particles and CBD particles according to embodiments of the invention, as described in Example 2. -
FIG. 8 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 3. -
FIG. 9A shows the particle size distribution of both THC particles and CBD particles according to embodiments of the invention, andFIG. 9B shows the particle size distribution of blank porous bead cores, as described in Example 3. -
FIGS. 10A-10F shows SEM images of THC and CBD particles and blank porous bead cores particles according to embodiments of the invention, as described in Example 3.FIGS. 10A-10C shows SEM images of THC and CBD particles at magnifications of 190× (FIG. 10A ), 1600× (FIG. 10B ), and 2200× (FIG. 10C ).FIGS. 10D-10F shows blank porous bead cores at magnifications of 220× (FIG. 10D ), 1000× (FIG. 10E ), and 1600× (FIG. 10F ). -
FIG. 11 shows the dissolution profile of both THC particles and CBD particles according to embodiments of the invention, as described in Example 3. -
FIGS. 12A and 12B show the dissolution profile of IR Reference Compositions A-C (FIG. 12A ) and the dissolution profile of extended release Example Compositions A-C according to embodiments of the invention (FIG. 12B ), as described in Example 4. -
FIG. 13 shows the dissolution profiles of extended release Example Compositions D-H according to embodiments of the invention, as described in Example 5. -
FIGS. 14A and 14B show the dissolution profile of immediate release Reference Composition D (FIG. 14A ) and the dissolution profile of extended release Example Composition I according to embodiments of the invention (FIG. 14B ), as described in Example 6. -
FIGS. 15A and 15B show the dissolution profile of immediate release Reference Composition E (FIG. 15A ) and the dissolution profile of extended release Example Composition J according to embodiments of the invention (FIG. 15B ), as described in Example 7. -
FIGS. 16A and 16B show the dissolution profile of immediate release Reference Composition F (FIG. 16A ) and the dissolution profile of extended release Example Composition K according to embodiments of the invention (FIG. 16B ), as described in Example 8. -
FIGS. 17A-17F shows SEM images of plain Neusilin US2 beads at magnifications of 220× (FIG. 17A ), 1000× (FIG. 17B ), and 1600× (FIG. 17C ); and of Neusilin US2 beads loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 190× (FIG. 17D ), 1600× (FIG. 17E ), and 2200× (FIG. 17F ). -
FIGS. 18A and 18B shows particles size distribution profiles of a composition of plain Neusilin US2 beads (FIG. 18A ) and a composition of Neusilin US2 beads loaded with THC and CBD in sesame oil according to embodiments of the invention (FIG. 18B ). -
FIGS. 19A and 19B show the dissolution profile of extended release Example Composition L according to embodiments of the invention (FIG. 19A ) and the dissolution profile of extended release Example Composition M according to embodiments of the invention (FIG. 19B ), as described in Example 9. -
FIG. 20 shows an SEM image of a particle of extended release Example Composition L according to embodiments of the invention, as described in Example 9. -
FIGS. 21A and 21B show the dissolution profile of immediate release Reference Composition F (FIG. 21A ) and the dissolution profile of extended release Example Composition N according to embodiments of the invention (FIG. 21B ), as described in Example 10. -
FIGS. 22A and 22B show the dissolution profile of immediate release Reference Composition G (FIG. 22A ) and the dissolution profile of extended release Example Composition O according to embodiments of the invention (FIG. 22B ), as described in Example 11. -
FIGS. 23A and 23B show the dissolution profile of immediate release Reference Composition H (FIG. 23A ) and the dissolution profile of extended release Example Composition I according to embodiments of the invention (FIG. 23B ), as described in Example 12. -
FIGS. 24A-24F shows SEM images of plain Cellets at magnifications of 30× (FIG. 24A ), 120× (FIG. 24B ), and 250× (FIG. 24C ); and of Cellets loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 50× (FIG. 24D ), 120× (FIG. 24E ), and 450× (FIG. 24F ). -
FIGS. 25A-25F shows SEM images of plain Suglets® 40/45 at magnifications of 50× (FIG. 25A ), 200× (FIG. 25B ), and 400× (FIG. 25C ); and ofSuglets® 40/45 loaded with THC and CBD in sesame oil according to embodiments of the invention at magnifications of 50× (FIG. 25D ), 200× (FIG. 25E ), and 600× (FIG. 25F ). -
FIGS. 26A and 26B show particle size distribution of plain Cellets (FIG. 26A ) and Cellets loaded with CBD according to embodiments of the invention (FIG. 26B ). -
FIGS. 27A and 27B show particle size distribution of plain Suglets® 40/45 (FIG. 27A ) andSuglets® 40/45 loaded with CBD according to embodiments of the invention (FIG. 27B ). - According to the present invention, multiparticulate dosage forms are provided for administering two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In certain embodiments, a final composition may comprise the two or more active agents in an amount of about 1% to about 90% w/w, or about 5% to about 50% w/w.
- An aspect of the invention relates to immediate release, extended release, or sustained release compositions comprising a population of particles that contain the two or more active agents. These compositions may be provided in a dosage form such as a tablet (for example, an ODT, self-disintegrated tablet, or chewable tablet), capsule, or stick pack.
- Other aspects of the invention relate to methods of preparing the compositions of the present invention, and methods of treatment involving administering the compositions of the present invention.
- The compositions of the present invention comprise two or more active agents, in which the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent. The at least one cannabinoid may comprise THC, CBD, or a combination thereof.
- The at least one non-cannabinoid therapeutic agent may be selected from active agents that can be used to help treat the various health conditions encompassed by the methods of treatment according to the present invention. In some embodiments, the at least one non-cannabinoid therapeutic agent may be selected from a group consisting of alcohol deterrents, such as disulfiram, naltrexone, acamprosate, gabapentin, and topiramate; analgesics and/or anti-inflammatory agents such as aloxiprin, auranofin, azapropazone, benorylate, diflunisal, etodolac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, and sulindac; antipyretics, such as acetaminophen, aspirin, ibuprofen, sodium salicylate, acetylsalicylic acid and naproxen; anorexigenic agents and respiratory and CNS stimulants, such as caffine, mazindol, carboxymethylcellulose, phenylpropanolamine, ephedrine, pseudoephedrine, amfepramone, methamphetamine, phentermine, and chlorphenamine; antiarrhythmic agents, such as amiodarone, disopyramide, flecainide acetate, and quinidine sulphate; anticholinergic agents, such as amitriptyline, atropine, benztropine, chlorpheniramine, chlorpromazine, clomipramine, clozapine, cyclobenzaprine, cyproheptadine, desipramine, dexchlorpheniramine, dicyclomine, diphenhydramine, doxepin, fesoterodine, hydroxyzine, hyoscyamine, imipramine, meclizine, nortriptyline, olanzapine, orphenadrine, oxybutynin, paroxetine, perphenazine, prochlorperazine, promethazine, protriptyline, pseudoephedrine hcl/triprolidine hcl, scopolamine, thioridazine, tolterodine, trifluoperazine, and trimipramine; anticonvulsants, such as acetazolamide, carbamazepine, clobaz, clonazepam, diazepam, ethosuximide, fosphenytoin, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, methsuximide, nitrazepam, oxcarbazepine, paraldehyde, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, stiripentol, topiramate, valproic acid, vigabatrin, felbamate, tiagabine hydrochloride, zonisamide; antidepressants, such as amoxapine, ciclazindol, maprotiline, mianserin, nortriptyline, trazodone, trimipramine maleate, acetohexamide, chlorpropamide, glibenclamide, gliclazide, glipizide, tolazamide, and tolbutamide; antidiabetic agents, such as acarbose, miglitol, pramlintide, alogliptan, linagliptan, saxagliptin, sitagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, insulin, nateglinide, repaglinide, metformin, canagliflozin, dapagliflozin, empagliflozin, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, rosiglitazone, and pioglitazone; antidiarrheal agents, such as attapulgite, bismuth subgallate, bismuth subsalicylate, atropine, loperamide, and diphenoxylate; antidotes; antiemetics, such as hyoscyamine, methscopolamine, scopolamine, cyclizine, dimenhydrinate, hydroxyzine, meclizine, promethazine, dronabinol, nabilone, tetrahydrocannabinol, chlorpromazine, prochlorperazine, alosetron, dolasetron, granisetron, ondansetron, palonosetron, aprepitant, fosaprepitant, rolapitant, dexamethasone, metoclopramide, and trimethobenzamide; antigout agents, such as probenecid, sulfinpyrazone, allopurinol, and colchicine; antihistamine drugs, such as acrivastine, astemizole, cinnarizine, cyclizine, cyproheptadine, dimenhydrinate, flunarizine, loratadine, meclozine, oxatomide, terfenadine, and triprolidine; anti-infective agents, including antibiotics, antifungals, antiparasitic agents, and antivirals; antimigraine agents, such as dihydroergotamine mesylate, ergotamine tartrate, methysergide maleate, pizotifen maleate, and sumatriptan succinate; antineoplastic agents, including alkylating agents, antimetabolites, mitotic inhibitors, and hormonal agents; antiparkinsonian agents, such as bromocriptine mesylate and lysuride maleate; antipsychotics, such as chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, haloperidol, lithium, loxapine, molindone, pimozide, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, pimavanserin, quetiapine, risperidone, and ziprasidone; antitussives, antiulcer agents and acid suppressants, antivirals, anxiolytics including sedatives and/or hypnotics, such as alprazolam, amyiobarbitone, barbitone, bentazeparn, bromazepam, bromperidol, brotizoiam, butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine, clobazam, clotiazepam, clozapine, diazepam, droperidol, ethinamate, flunanisone, flunitrazepam, fluopromazine, flupenuiixol decanoate, fluphenazine decanoate, flurazepam, haloperidol, lorazepam, lormetazepam, medazepam, meprobamate, methaqualone, midazolam, nitrazepam, oxazepam, pentobarbitone, perphenazine pimozide, prochlorperazine, suipiride, temazepam, thioridazine, triazolam, and zopiclone; atypical antipsychotics, corticosteroids, such as beclomethasone, betamethasone, budesonide, cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate, flunisolide, flucortolone, fluticasone, propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone; gastrointestinal drugs, hypotensive agents, such as amlodipine, carvedilol, benidipine, darodipine, diltiazem, diazoxide, felodipine, guanabenz acetate, indoramin, isradipine, minoxidil, nicardipine, nifedipine, nimodipine, phenoxybenzamine, prazosin, reserpine, and terazosin; immunosuppressive agents, miscellaneous therapeutic agents, monoamine oxidase inhibitors, NSAIDs, opiate agonists or opiate partial agonists, such as codeine, dextropropyoxyphene, diamorphine, dihydrocodeine, meptazinol, methadone, morphine, nalbuphine, and pentazocine; respiratory tract agents, skeletal muscle relaxants, thyroid and anti-thyroid agents, such as carbimazole and propylthiouracil; tricyclics and other norepinephrine-reuptake inhibitors, vitamins, wakefulness-promoting agents, sildenafil, tadalafil or combinations thereof.
- The compositions of the present invention may be an immediate release composition, extended release composition, or a sustained release composition.
- In embodiments of the invention, the immediate release compositions of the present invention may comprise particles, in which each particle may comprise at least one active agent and one or more intra-granular excipients. The one or more intra-granular excipients may comprise one or more diluents, one or more binders, one or more fillers, one or more surfactants/emulsifying agents, one or more disintegrants, or a combination thereof.
- In embodiments of the invention, the immediate release compositions of the present invention may comprise particles, in which each particle may comprise at least one active agent and a porous bead core. The porous bead core may be a carrier for the absorption and release of liquids, e.g., silica bead. In some embodiments of the invention, the core may comprise a silica bead, a biodegradable glass bead, or any other bead made of any compatible materials known in the art as suitable for oral administration (e.g., porous ceramics, porous calcium carbonate particles, porous zeolite particles, etc.).
- The core may comprise one or more pores that extend from the surface of the core. The core may contain the one or more cannabinoids. According to some embodiments, the ratio of pore volume to particle size of the core may be between about 0.001 to about 0.8.
- According to the present invention, the core is selected to achieve a free flowing multiparticulate system. According to some embodiments, the core may comprise mesoporous silica (e.g. Syloid® XDP 3150 (Grace, USA), Davisil® LC150A (Grace, USA), Neusilin® US2 (Fuji Chemicals, Japan)).
- The at least one active agent may comprise at least one cannabinoid, at least one non-cannabinoid therapeutic agent, or a combination of at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both at least one cannabinoid and at least one non-cannabinoid therapeutic agent, then the particles in the immediate release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- The immediate release composition of the present invention may release a particular percentage of the active agents (i.e., the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent) within a certain amount of time, as determined by dissolution testing.
- The dissolution test may be performed under the conditions summarized in Table 1 below.
-
TABLE 1 Conditions used for dissolution testing according to embodiments of the invention. Parameter Condition Apparatus USP II (Paddle) Paddle Speed 100 rpm Media 1 % Polysorbate 80 inDW Media Volume 500 ml Temperature 37° C. Sampling Time Point(s) 15, 30, 60, 240, 360, 720 min - In some embodiments, the composition of the present invention may release about 30% or greater of the one or more cannabinoids over a period of about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test. In some embodiments, the composition may release about 50% or greater of the one or more cannabinoids over a period of about 60 minutes (1 hour) or less, or about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test. In some embodiments, the composition may release about 80% or greater of the one or more cannabinoids over a period of about 90 minutes (1.5 hours) or less, or about 60 minutes (1 hour) or less, or about 30 minutes (0.5 hours) or less, or about 15 minutes (0.25 hours) or less, or about 10 minutes or less, from the start of the dissolution test.
- The composition of the present invention may comprise particles having a particular size distribution. For example, in some embodiments, about 80% of the particles may between about 20 □m and about 2000 □m in diameter, or between about 30 □m and about 1000 □m in diameter, or between about 40 □m and about 900 □m in diameter. In some embodiments, about 80% of the particles may between about 2 □m and about 500 □m in diameter, or between about 4 □m and about 300 □m in diameter, or between about 5 □m and about 200 □m in diameter.
- As used herein, the term “extended release” is characterized by the gradual release of the active agents from the particles of the composition over an extended period of time, optionally greater than about 30 minutes. With extended release, the rate of release of the active agents from the particles is controlled in order to maintain therapeutic activity of the active agents for a longer period of time. In some embodiments of the current invention, the composition may release greater than about 40% of the one or more active agents over a period of about 6 hours or more. In certain embodiments, the composition may release the one or more active agents over a period of about 12 hours to about 24 hours.
- As used herein, the term “solubilizer” refers to a solubility enhancement excipient that increases the bioavailability of the one or more active agents. The purpose of the one or more solubilizers is to achieve a concentrated, homogenous, and stable solution in order to deliver the one or more active agents in an efficient way. The one or more solubilizers for use in the present invention may include, but are not limited to, oil, glyceride, an alcohol, or a combination thereof. The oil may be selected from the group consisting of cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, almond oil, sesame oil, rapeseed oil, peppermint oil, poppy seed oil, canola oil, palm kernel oil, hydrogenated soybean oil, hydrogenated vegetable oil, and a combination thereof. The glyceride may be selected from the group consisting of a monoglyceride, diglyceride, triglyceride, and a combination thereof. The alcohol may be a monohydric alcohol, e.g., ethanol, methanol, or isopropyl alcohol. In some embodiments, the one or more solubilizers may be a hydroalcoholic mixture.
- As used herein, the term “drug-releasing agents” relates to agents that control drug delivery so that the active agents are released in a predesigned manner. As a result, the drug-releasing agents contribute to the rate and extent of the cannabinoids' active availability to the body.
- As used herein “stabilizing agents” may include, but are not limited to, tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, isoascorbic acid, potassium salt of sulfurous acid (e.g., potassium metabisulfite), sodium salt of sulfurous acid (e.g., sodium met abisulfite), vitamin E, lecithin, ascorbyl palmitate, edetic acid, edetate salt (e.g., EDTA), or a combination thereof. The stabilizing agents may be present in the composition in an amount of about 0.001% to about 5% by weight, or as suitable in order to achieve a stabilized composition.
- In embodiments of the invention, the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent, one or more lipid-based gel-forming agents, and a porous core. In some embodiments, the particles may comprise at least one active agent, one or more lipid-based gel-forming agents, a porous core, one or more solubilizers, and one or more surfactants. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- In some embodiments, the particles may comprise one or more stabilizing agents.
- The one or more gel-forming agents may be selected from glyceryl monooleate (e.g., Capmul GMO-50; Abitec Corp., USA), glycerol monostearate (e.g., Geleol™ Mono and Diglycerides; Gattefosse, USA), glyceryl distearate, polyglyceryl-3 dioleate (Geloil®; Gattefosse, USA), soybean oil, propylene glycol monopalmitostearate (e.g., Monosteol™; Gattefosse, USA), cellulose-based gelling agents, carboxypolymethylenes (e.g., Carbopol® or Carbomer®), hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, chitosan, natural gums (e.g., acacia, alginates, carrageen, guar gum), and a combination thereof. In certain embodiments, the one or more gel-forming agents may comprise glycerol monooleate.
- In embodiments in which the composition comprises one or more gel-forming agents and one or more surfactants, the weight ratio of the one or more gel-forming agents to the one or more surfactants may be about 10:1 to about 1:10, or about 8:1 to about 1:8, or about 5:1 to about 1:5. According to certain embodiments, the ratio of the one or more gel-forming agents to the one or more surfactants may be about 1:1. In certain embodiments, cellulose-based and gum-based gelling agents can be added with or without surfactants.
- The porous core may be the same as the porous bead core described above for the immediate release composition. The core may contain the at least one active agent, the one or more solubilizers, and the one or more gel-forming agents. According to some embodiments, the ratio of pore volume to particle size of the core may be between about 0.001 to about 0.8. Within that range, the pores may be configured such that the one or more gel-forming agents are located in the pores closer to the surface of the core than the at least one active agent and the one or more solubilizers. In embodiments wherein one or more solubilizers and one or more surfactants are in the composition, the pores may be configured such that the one or more gel-forming agents are located in the pores closer to the surface of the core than the at least one active agent, the one or more solubilizers, and the one or more surfactants.
- According to the present invention, the core is selected in consideration of loading capacity and its capability of achieving a free-flowing multiparticulate system. According to some embodiments, the core comprises mesoporous silica (e.g. Syloid® XDP 3150 (Grace, USA), Davisil® LC150A (Grace, USA), Neusilin® US2 (Fuji Chemicals, Japan)). Particle size, pore volume and specific surface area for the silica beads are given in Table 2 below.
-
TABLE 2 Physical properties of silica beads Syloid ® Davisil ® Neusilin ® Physical properties XDP 3150 LC150A US2 Particle Size Distribution (μm) 120-170 315-500 44-177 Specific Surface Area (m2/g) 320 340 300 Pore Volume (ml/g) 1.7 1.23 1.2 Ratio of pore volume to 0.014 0.003 0.020 particle size Oil Adsorption Capacity 300 — 270-340 (g/100 g) Angle of Repose (°) 36 36 30 - The ratio of pore volume to particle size was determined using dynamic light scattering technique and was highest for Neusilin US2 beads. The particle size distribution for the Neusilin US2 beads is shown in
FIG. 1A having d90 as 108 □m and a bimodal distribution. Upon loading of 2:1 ratio of probucol (as a surrogate active ingredient), sesame oil, surfactant, and gel-forming lipid excipient to silica, the particle size distribution of the Neusilin US2 beads was changed to d90 of 182 μm having a unimodal distribution curve, as shown inFIG. 1B . Scanning electron microscopy images for both plain and loaded Neusilin US2 beads are illustrated inFIGS. 2A and 2B . In particular,FIG. 2A depicts plain Neusilin US2 beads andFIG. 2B depicts Neusilin US2 beads loaded with probucol (as a surrogate active ingredient) in sesame oil and a surfactant. - Selection of silica beads considered their flowability upon maximum drug loading. Weight ratios 2:1, 3:1, and 4:1 of probucol (as a surrogate active ingredient) in sesame oil and surfactant to silica were evaluated for the maximum drug loading capacity while retaining the free flowing capacity of the silica beads. Angle of repose of Syloid® XDP 3150 beads and Davisil® LC150A beads is between 35-40° representing passable flowability, as shown in Table 1. However, the angle of repose of Neusilin® US2 beads is 30°, shown in Table 2, which represents better flowability as compared to Syloid® XDP 3150 beads and Davisil® LC150A beads. Upon maximum drug loading, Syloid® XDP 3150 beads and Davisil® LC150A beads displayed a loss in their flowability when loaded with the 2:1 weight ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica. Neusilin® US2 beads retained their free flowing properties at the 2:1 and 3:1 weight ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica. However, at 4:1 ratio, the flowability of Neusilin® US2 beads appeared to be reduced. Therefore, based on evaluation, Neusilin® US2 beads were identified as a carrier substrate with optimized drug loading of 2:1 and 3:1 wieght ratio of probucol (as a surrogate active ingredient) in sesame oil, surfactant, and gel-forming excipient to silica. However, Syloid® XDP 3150 and Davisil® LC150A carrier substrates nonetheless display properties that are conducive for use as the core in the compositions of the present invention.
- In embodiments of the invention, one or more surfactants are used in the composition. In the current invention, surfactants are included to maximize the complete release of the one or more active agents from the pores of the cores. The active agents may be hydrophobic and their release upon dissolution in aqueous medium of the gastrointestinal tract is determined by various intrinsic factors such as fluid volume, peristaltic movement, concentration gradient, food effect, bile salts, and transit time. Since the loading of the one or more active agents onto porous cores is achieved by the capillary action and in consideration of the greater affinity of hydrophobic active agents to the cores, the release of the one or more active agents from the pores warrants an emulsification action.
- In embodiments of the invention, the extended release composition may comprise a population of particles, wherein each particle comprises: at least one active agent; one or more drug-releasing agents that comprise one or more release-controlling polymers, one or more release-accelerating polymers, or a combination thereof; and an inert core. In some embodiments, the particles may comprise at least one active agent; one or more drug-releasing agents that comprise one or more release-controlling polymers, one or more release-accelerating polymers, or a combination thereof; an inert core; and one or more solubilizers. The at least one active agent may comprise the at least one cannabinoid, the at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent. In embodiments in which each particle does not comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, then the population of particles in the extended release composition may comprise both particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent.
- In some embodiments, the particles may comprise one or more stabilizing agents.
- The one or more release-controlling polymers may be selected from, for example, ethyl cellulose, polymethacrylate copolymers, copolymers derived from esters of acrylic and methacrylic acid (e.g., Eudragit® such as Eudragit® L-30D, Eudragit® FS-30D), polyacrylic acid-based polymers, polyacrylates, methacrylic acid co-polymers, polyvinyl acetate (e.g., Kollicoat® SR-30D), polyvinyl alcohol, and combinations thereof. The one or more release-accelerating polymers may be selected from polyvinylpyrrolidones or cellulose derivatives that are water soluble. The early dissolution of these ingredients leave pores on and around the coated material applied on the inert substrates through which one or a combination of active agents is released by diffusion. Diffusion is defined as a process of drug transport from a region of high concentration to a region of low concentration.
- According to embodiments of the current invention, the core may comprise an inert material selected from the group consisting of microcrystalline cellulose, celluloses, starches, and saccharides; natural polymers that include, but are not limited to, chitosan, alginate, and collagen protein/polypeptides; synthetic polymer-based materials that include, but are not limited, to polylactic acid, polycaprolactone, polyglycolic acid, and polylactic-co-glycolic acid; ceramics that include, but are not limited to, calcium phosphate, hydroxyapatite, and □-tricalcium phosphate; glass that include, but are not limited to, borate-based glass, silicate-based glass, and phosphate-based glass; and combinations thereof.
- In some embodiments, the core may comprise a coating that comprises the one or more active agents; and the one or more release-controlling polymers, the one or more release-accelerating polymers, or a combination thereof.
- In embodiments of the present invention, the composition of the present invention can exhibit a dissolution profile that is characteristic of extended release. In some embodiments, when subjected to water as a dissolution medium, the composition of the present invention may exhibit a percent release of the one or more active agents of not more than about 20%, or not more than about 30%, or not more than about 40%, or not more than about 50% by weight, after 30 minutes; or not more than about 30%, or not more than about 40%, or not more than about 50%, or not more than about 60% by weight, after 60 minutes; or not more than about 40%, or not more than about 50%, or not more than about 60%, or not more than about 70% by weight, after 120 minutes.
- The composition of the present invention may be in various dosage forms, for example, in capsules, tablets (including regular tablets, ODT, self-disintegrated tablets, chewable tablets), sachets, sprinkles, or a stick pack. To this end, the composition may comprise excipients such as binding agents, fillers, lubricants, disintegrants, antioxidants, wetting agents, flavors/sweeteners, or a combination thereof.
- The compositions of the present invention may comprise one or more excipients. As described herein, in some embodiments the immediate release composition may comprise a population of particles, in which each particle includes one or more intra-granule excipients, such as one or more diluents, one or more binders, one or more fillers, one or more surfactants/emulsifying agents, one or more disintegrating agents, or a combination thereof. Also, in some embodiments the extended release composition may comprise a population of particles, in which each particle may comprise one or more excipients such as one or more surfactants. In addition, the dosage forms of the compositions may comprise one or more excipients such as one or more binding agents, fillers, surfactants, lubricants, disintegrants, antioxidants, wetting agents, or flavors/sweeteners.
- Diluents may serve different functions, such as to increase weight and improve content uniformity, improve cohesion, and/or promote flow. Examples of diluents include, but are not limited to, cellulose derivatives such as lactose, sucrose, isomalt, cellulose, starch, cyclodextrin, mannitol, microcrystalline cellulose, and sorbitol; calcium carbonate; plain or anhydrous calcium phosphate; calcium hydrogen phosphate dehydrate; calcium phosphate di- or tri-basic; magnesium carbonate; magnesium oxide; starch; sodium chloride; and a combination thereof.
- Binders are excipients that may act as an adhesive to “bind together” particles and, in some cases, impart mechanical strength. In addition, binders can also provide volume to the composition. Examples of binders may include, but are not limited to, sugars such as sucrose, lactose, and glucose; corn syrup; soy polysaccharide; gelatin; povidone (e.g., Kollidon®, Plasdone®); Pullulan; cellulose derivatives such as microcrystalline cellulose, hydroxypropylmethyl cellulose (e.g., Methocel), hydroxypropyl cellulose (e.g., Klucel®), ethylcellulose, hydroxyethyl cellulose, carboxymethylcellulose sodium, and methylcellulose; acrylic and methacrylic acid co-polymers; carbomer (e.g., Carbopol®); polyvinylpolypyrrolidine, polyethylene glycol (Carbowax®); pharmaceutical glaze; alginates such as alginic acid and sodium alginate; gums such as acacia, guar gum, and arabic gums; tragacanth; dextrin and maltodextrin; milk derivatives such as whey; starches such as pregelatinized starch and starch paste; hydrogenated vegetable oil; magnesium aluminum silicate; and a combination thereof.
- Fillers may increase the bulk of the composition and may make it easier to handle. Examples of fillers may include, but are not limited to, lactose, dextrose, saccharose, cellulose, starch, calcium phosphate, sucrose, dextrates, dextrin, maltodextrin, microcrystalline cellulose (e.g., PH102 or PH200, Avicel®), microfine cellulose, powdered cellulose, pregelatinized starch (e.g., Starch 1500®), calcium phosphate dihydrate, soy polysaccharide (e.g., Emcosoy®), gelatin, silicon dioxide, calcium sulfate, calcium carbonate, magnesium carbonate, magnesium oxide, sorbitol, mannitol, kaolin, polymethacrylates (e.g., Eudragit®), potassium chloride, sodium chloride, talc, and a combination thereof.
- Disintegrants may assist in breaking up the particles when exposed to an aqueous environment. Examples of disintegrants may include, but are not limited to, modified sodium starch glycolate, cross-linked povidone or crospovidone (e.g., Kollidon®), hydroxyl propyl cellulose, starch, alginic acid, sodium alginate, sodium carboxy-methylcellulose, croscarmellose sodium, carmellose sodium, microcrystalline cellulose, carboxystarch sodium, carboxymethyl starch sodium, potato starch, wheat starch, corn starch, rice starch, partly pregelatinized starch, hydroxypropyl starch, alginates, carbonates, and a combination thereof.
- Surfactants/emulsifying agents promote self-emulsification. When an emulsion is formed, surface area expansion is created between the two phases. The emulsion is stabilized by the surfactant/emulsifying agent molecules that form a film around the internal phase droplet. In emulsion formation, the excess surface free energy is dependent on the droplet size and the interfacial tension. If the emulsion is not stabilized using surfactants/emulsifying agents, the two phases will separate reducing the interfacial tension and the free energy. Self-emulsifying drug delivery systems (“SEDDS”) including self-micro-emulsifying drug delivery systems (“SMDDS”) are mixtures of natural or synthetic oils, solid or liquid surfactants/emulsifying agents, or alternatively, one or more hydrophilic solvents and co-solvents/surfactants/emulsifying agents that have the ability to form oil-in-water emulsions upon mild agitation followed by dilution in aqueous media, such as gastrointestinal fluids. Examples of surfactants/emulsifying agents may include, but are not limited to, sorbitan esters, ethoxylated sorbitan esters (
Tween® 80; Sigma Aldrich, USA), ethoxylated linear alcohols, ethoxylated alkyl phenols, fatty acid esters, amine and amide derivatives, alkylpolyglucosides, ethyleneoxide/propylene oxide copolymers, polyalcohols and ethoxylated polyalcohols, thiols (e.g., mercaptans) and derivatives, poloxamers, polyethylene glycol-fatty acid esters, lecithins, and mixtures thereof. In certain embodiments, the surfactant/emulsifying agent may be selected from polysorbates (Tween® 80; Sigma Aldrich, USA), and polyethylene glycol esters of ricinoleic acid (Kolliphor® RH40, Kolliphor® EL; BASF, Germany). - Lubricants may reduce friction between granules and thus enhance followability, as well as prevent sticking to die wall in tablet compression and facilitate powder-filling in encapsulation. Lubricants may also assist with disintegration time and impact dissolution rate. Examples of lubricants may include, but are not limited to, calcium stearate, castor oil hydrogenated, glyceryl monostearate, glyceryl behenate, magnesium stearate, mineral oil, polyethylene glycol, polaxamer 407 or 188 or plain, sodium lauryl sulfate, sodium benzoate, stearic acid, sodium stearyl fumarate, silica, talc, and a combination thereof.
- Antioxidants can have positive effects on the stability and efficacy of the composition. Examples of antioxidants may include, but are not limited to, acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), monothioglycerol, potassium nitrate, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfite, vitamin E or a derivative thereof, propyl gallate, edetate (EDTA) (e.g., disodium edetate), diethylenetriaminepentaacetic acid (DTPA), triglycollamate (NT), and a combination thereof. Antioxidants may also comprise amino acids such as methionine, histidine, cysteine and those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid. Any stereoisomer (e.g., L-, D-, or a combination thereof) of any particular amino acid (e.g., methionine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and combinations thereof) or combinations of these stereoisomers, may be present so long as the amino acid is present either in its free base form or its salt form. For example, the L-stereoisomer may be used.
- Flavors/sweeteners can help make the composition more palatable. Examples of flavors/sweeteners may include, but are not limited to, sugar, dextrose, fructose, aspartame, glycerin, mannitol, sucrose, saccharin sodium, acesulfame potassium, dextrates, liquid glucose, maltitol, saccharin, saccharin calcium; saccharin sodium, sodium cyclamate, sorbitol, stevia, syrup, xylitol, and a combination thereof.
- As used herein, the term “sustained release” is characterized by the continuous release of the active agents from the particles of the composition over a prolonged period of time, optionally greater than about 60 minutes.
- The sustained release composition may comprise a population of particles comprising one or more of the particles of the immediate release composition of the present invention, and one or more of the particles of the extended release composition of the present invention. The amounts of the particles of the immediate release composition and the particles of the extended release composition may be based on achieving a pre-determined release profile.
- In some embodiments, the release profile may comprise a rapid release of the active agents, followed by a more gradual release of the active agents. For example, the rapid release may comprise about 30% to about 70% by weight of the total active agents, or about 40% to about 60% by weight of the total active agents, released within about 60 minutes (1 hour) or less, or about 30 minutes or less, or about 15 minutes or less. The gradual release may comprise the remaining about 30% to about 70% by weight of the total active agents, or the remaining about 40% to about 60% by weight of the total active agents, released after about 60 minutes (1 hour), or after about 120 minutes (2 hours), or after about 180 minutes (3 hours), or after about 240 minutes (4 hours). In some embodiments, the release of the active agents may be prolonged up to 1440 minutes (24 hours), as intended for the therapeutic effect.
- In embodiments of the invention, methods of preparing immediate release compositions of the present invention may comprise (a) combining the at least one active agent with one or more intra-granular excipients, and granulating the combination to produce immediate release particles; or (b) loading the at least one active agent onto porous bead cores to produce immediate release particles.
- The at least one active agent used in the methods above may comprise at least one cannabinoid, or at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In embodiments in which the at least one active agent used in the methods above is not a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent, then the methods may comprise preparing immediate release particles that comprises the at least one cannabinoid as the at least one active agent, preparing immediate release particles that comprises the at least one non-cannabinoid therapeutic agent as the at least one active agent, and then combining the immediate release particles comprising at least one cannabinoid and the immediate release particles comprising the at least one non-cannabinoid therapeutic agent to form the immediate release composition. Such a combination may occur, for example, by granulating particles comprising the at least one cannabinoid and particles comprising the at least one non-cannabinoid therapeutic agent into one granulation. Alternatively, such a combination may occur, by mixing a population of particles comprising the at least one cannabinoid and a population of particles comprising the at least one non-cannabinoid therapeutic agent.
- The at least one active agent that is combined with the one or more intra-granular excipients or that is loaded onto porous bead cores may be in a granulating liquid. The granulating liquid may be an emulsion, suspension, hydroalcoholic mixture, or a combination thereof. In some embodiments, the granulating liquid may comprise one or more solubilizing agents. The one or more solubilizing agents may be an oil, a glyceride, an alcohol, a hydroalcoholic solution, or a combination thereof. Examples of an oil may include, but are not limited to, sesame oil, cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, almond oil, rapeseed oil, peppermint oil, poppy seed oil, canola oil, palm kernel oil, hydrogenated soybean oil, hydrogenated vegetable oil, and a combination thereof. Examples of a glyceride may include, but are not limited to, a monoglyceride, diglyceride, triglyceride, and a combination thereof. Examples of an alcohol may include, but are not limited to, a monohydric alcohol, e.g., ethanol, methanol, or isopropyl alcohol. Examples of a hydroalcoholic mixture may include, but are not limited to, isopropyl alcohol mixed with water, or ethanol mixed with water, in varying ratios.
- In some embodiments, the granulating liquid may further comprise one or more surfactants/emulsifying agents.
- In some embodiments, the methods of the invention further comprise preparing the granulating liquid comprising the at least one active agent. Preparation of the granulating liquid may involve mixing the at least one active agent with the one or more solubilizing agents until the at least one active agent is dissolved. In some embodiments, preparation of the granulating liquid may comprise mixing other components, such as one or more surfactants/emulsifying agents, with the at least one active agent and the one or more solubilizing agents. The mixing of the contents may be by methods known in the art. For example, the contents may be mixed by simple mixing, or may be mixed with a mixing device continuously, periodically, or a combination thereof. Examples of mixing devices may include, but are not limited to, a magnetic stirrer, shaker, a paddle mixer, homogenizer, and any combination thereof.
- In embodiments in which the particles comprise both at least one cannabinoid and at least one non-cannabinoid therapeutic agent, the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent may be in the same granulating liquid, or may be in different granulating liquid.
- In embodiments in which the particles comprise both THC and CBD, the THC and CBD may be in the same granulating liquid, or may be in different granulating liquids.
- In embodiments of the invention, the granulating liquid may be combined with one or more intra-granular excipients, and the combination may be granulated to produce immediate release particles. The combination of the granulating liquid may occur before granulation, or may occur concurrently in whole or in part with granulation.
- In embodiments in which the particles comprise both the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent, and in which the at least one cannabinoid and the at least one non-cannabinoid therapeutic agent are in different granulating liquids, the granulating liquid may be combined together before combining with the one or more intra-granular excipients. Alternatively, the granulating liquid may be combined together simultaneously with combining with the one or more intra-granular excipients.
- In embodiments in which the particles comprise both THC and CBD, and in which the THC and CBD are in different granulating liquids, the granulating liquids may be combined together before combining with the one or more intra-granular excipients. Alternatively, the granulating liquids may be combined together simultaneously with combining with the one or more intra-granular excipients.
- In some embodiments, the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a fluid bed granulation process. The one or more intra-granular excipients may be loaded into a granulator bowl of a fluid bed granulator and fluidized. The granulating liquid(s) may be added into the granulator bowl and onto the one or more intra-granular excipients. The addition of the granulating liquid(s) may be via a top spray, bottom spray, tangential spray, or an equivalent thereof. The parameters of this process, including the amount of pressure necessary to fluidize the one or more excipients in the granulator bowl, the inlet air temperature in the granulator bowl, the humidity level in the granulator bowl, the spray rate of the granulating liquid(s), and the fluid bed spray nozzle size and height, can all be determined by one of ordinary skill in the art. Examples of fluid bed granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, Sainty International Group, GEA Group, Senieer, LB Bohle, Robert Bosch Packaging Technology GmbH, and SPX FLOW Danmark.
- In some embodiments, the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a wet granulation process. In certain embodiments, the wet granulation process may be performed with a high-shear granulator. The one or more intra-granular excipients may be loaded into a bowl of a high-shear granulator and mixed at speeds ranging from about 25 rpm to about 1000 rpm, or about 100 rpm to about 500 rpm. The granulating liquid(s) may be added into the granulator bowl and onto the one or more intra-granular excipients, and the combination of the granulating liquid(s) and the one or more excipients is mixed under high shear at speeds ranging from about 500 rpm to about 5000 rpm, or about 1000 rpm to about 3000 rpm. The parameters of this process, such as the addition rate of the granulating liquid(s), can all be determined by one of ordinary skill in the art. In some embodiments, the high-shear granulator may be a vertical high-shear granulator. The vertical high-shear granulator may be top-driven or bottom-driven. In other embodiments, the high-shear granulator may be a horizontal high-shear granulator. Examples of high-shear granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, SERVOLiFT LLC, Sainty International Group, GEA Group, Senieer, LB Bohle, and Robert Bosch Packaging Technology GmbH.
- In certain embodiments, the wet granulation process may be performed with the Glatt CPS' technology (Complex Perfect Spheres Technology). CPS™ is a patented technology by Glatt GMBH in which spherical granules are manufactured in two phases (i) nucleation of powders in which the solvent acts as a binder to create bridges between the particles of the active ingredient and a filler (e.g., microcrystalline cellulose), resulting in agglomeration; and (ii) spheronization of the granules due to centrifugal force exerted by the simultaneous spinning of the modified rotor disc to produce the smooth spherical granules/pellets. The CPS technology is disclosed in U.S. Pat. No. 6,354,728 and PCT Publication No. WO04052607, which are incorporated herein by reference. The one or more intra-granular excipients may be loaded into a bowl and the granulating liquid(s) may be added into the bowl and onto the one or more excipients.
- In certain embodiments, the wet granulation process may be performed by extrusion-spheronization. The one or more intra-granular excipients may be loaded into a bowl and the granulating liquid(s) may be added into the bowl and onto the one or more intra-granular excipients. The combination of the granulating liquid(s) and the one or more excipients may be mixed, such as with a planetary mixer, a high-shear mixer as described above, or a sigma blade mixer. The combination mixture may then undergo extrusion, in which pressure is applied to the combination mixture until it flows out through one or more orifices to produce the extrudates. Extrusion may be performed using a screw extruder, which uses a screw to develop the necessary pressure to force the combination mixture to flow through the one or more orifices; sieve extruder, which uses a rotating or oscillating arm to press the combination mixture through a sieve; basket extruder, which uses a rotating or oscillating arm to press the combination mixture through a sieve that is part of a vertical cylindrical wall; roll extruder, in which the combination mixture is fed between a roller and a perforated plate or ring due; ram extruder, in which the combination mixture compressed and forced through one or more orifices by a piston that is inside a cylinder or channel; or other types of extruders known in the art. The extruded combination mixture may then undergo spheronization, in which the mixture is broken into uniform lengths and are gradually transformed into spherical shapes. The parameters of the extrusion-spheronization process can be determined by one of ordinary skill in the art. Examples of extrusion-spheronization equipment that may be used in these methods of the invention may include those manufactured by Glatt GMBH, Sainty International Group, GEA Group, LB Bohle, and Robert Bosch Packaging Technology GmbH.
- In certain embodiments, the wet granulation process may be performed with a connection mixer, roller compactor, or “V” blender, using methods known in the art.
- Following wet granulation, the particles may be dried using methods known in the art, for example, using a fluid bed processor.
- In some embodiments, the combination of the granulating liquid(s) with the one or more intra-granular excipients and granulation may be performed by a spray granulation process. The granulating liquid(s), which includes one or more surfactants as described above, is mixed well with the one or more intra-granular excipients, resulting in a dispersion. This dispersion may comprise about 5% to about 90% of solid content. The dispersion is then sprayed onto a fluidized or spouted bed to produce particles. The parameters of this process can be determined by one of ordinary skill in the art. Examples of spray granulators that may be used in these methods of the invention may include those manufactured by Glatt GMBH, GEA Group, LB Bohle, Robert Bosch Packaging Technology GmbH, and Allgaier Werke GmbH.
- In certain embodiments, the spray granulation process may be performed using Procell® sprouted bed technology. The Procell technology is disclosed in U.S. Pat. Nos. 7,993,595 and 8,597,685, and in European Patent Nos. 1125629 and 1325775, which are all incorporated herein by reference.
- In embodiments of the invention, the granulating liquid(s) comprising the at least one active agent may be loaded onto porous bead cores. The granulating liquid(s) may be loaded onto the porous bead cores by mixing the granulating liquid(s) with the cores. In certain embodiments, a high shear granulator may be used to mix the granulating liquid(s) with the porous bead cores. In some embodiments, the mixing may occur until a free-flowing powder mixture is produced. Thereafter, a composition according to the present invention is formed.
- According to embodiments of the invention, the particles comprising the at least one active agent prepared by the methods described above may be sized, milled, and screened according to methods known in the art. The particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies. Particles comprising different active agents may be combined prior to processing them into the dosage form.
- In embodiments of the invention, methods of preparing extended release compositions of the present invention may comprise (a) mixing the at least one active agent in one or more solubilizers along with one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) and loading the mixture onto a porous core; or (b) dispersing the at least one active agent in one or more solubilizers along with one or more release-controlling polymers and/or one or more release-accelerating polymers (and optionally one or more stabilizing agents), and the drug dispersion may then be applied onto inert cores (such as microcrystalline cellets or sugar spheres).
- The at least one active agent used in the methods above may comprise at least one cannabinoid, or at least one non-cannabinoid therapeutic agent, or a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent. In embodiments in which the at least one active agent used in the methods above is not a combination of the at least one cannabinoid and at least one non-cannabinoid therapeutic agent, then the methods may comprise preparing extended release particles that comprises the at least one cannabinoid as the at least one active agent, preparing extended release particles that comprises the at least one non-cannabinoid therapeutic agent as the at least one active agent, and then combining the extended release particles comprising at least one cannabinoid and the extended release particles comprising the at least one non-cannabinoid therapeutic agent to form the extended release composition.
- In embodiments of the present invention, the methods comprise mixing the at least one active agent and the one or more gel-forming agents (and in some embodiments one or more surfactants, and optionally one or more stabilizing agents) in one or more solubilizers using, for example, a sonicator and/or a vortex mixer. These components may be mixed in the solubilizer(s) in any order (e.g., first mixing the at least one active agent in the one or more solubilizers and then adding the one or more gel-forming agents and in some embodiments the one or more surfactants, or first mixing one or more surfactants in the one or more solubilizers and then adding the at least one active agent and the one or more gel-forming agents, or adding and mixing each component simultaneously together, etc.). In some embodiments, the at least one active agent and the one or more solubilizers may be mixed with a sonicator until uniform, and then the one or more surfactants (in some embodiments) and the one or more gel-forming agents (and optionally one or more stabilizing agents) may be added and mixed using a vortex mixer. The mixture may then be loaded onto the porous cores by mixing the mixture with the cores. In certain embodiments, a high shear granulator may be used to mix the at least one active agents/one or more gel-forming agents/other components mixture with the porous cores. Thereafter, a composition according to the present invention is formed.
- In embodiments of the invention, the methods comprise mixing the at least one active agent in the one or more solubilizers to form a homogenous dispersion. The one or more release-controlling polymers and/or the one or more release-accelerating polymers) (and optionally one or more stabilizing agents) may be then mixed with the dispersion using, for example, a vortex mixer, until a homogenous mixture is formed. The mixture may be then loaded onto the cores. In some embodiments, the mixture may be sprayed onto the cores using, for instance, a fluid bed processor. The particle size and size distribution of the cores can be narrowed/adjusted to achieve uniform drug distribution and targeted delivery profile.
- The particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies. Particles comprising different active agents may be combined prior to processing them into the dosage form.
- In embodiments of the invention, methods of preparing sustained release compositions of the present invention may comprise mixing particles of the immediate release compositions of the invention with particles of the extended release compositions of the invention. The amount of the particles of the immediate release compositions and the amount of the particles of the extended release compositions may be based on achieving a pre-determined release profile.
- The particles may be mixed by simple mixing, or may be mixed with a mixing device continuously, periodically, or a combination thereof. Examples of mixing devices may include, but are not limited to, a magnetic stirrer, shaker, a paddle mixer, homogenizer, and any combination thereof.
- The particles may be blended with extra-granular excipients as described above, and the resulting blend may be processed into a dosage form such as a tablet, capsule, or stick pack using conventional methodologies. Particles comprising different active agents may be combined prior to processing them into the dosage form.
- An aspect of the invention relates to methods of treating a health issue in a subject in need thereof, wherein the methods comprise administering an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention.
- The present invention also relates to the use of an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention for treating a health issue in a subject in need thereof. The use may comprise administering the composition to the subject.
- The present invention relates to the use of an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention in the manufacture of a medicament for treating a health issue in a subject in need thereof.
- The present invention further relates to an immediate release composition of the invention, an extended release composition of the invention, or a sustained release composition of the invention for use in treating a health issue in a subject in need thereof. The use may comprise administering the composition to the subject.
- The health issue may be selected from the group consisting of pain, nausea, sleep apnea, stress disorders, inflammation, depression, anxiety, epilepsy, schizophrenia, migraines, arthritis, weight loss, poor appetite, and combinations thereof.
- In some embodiments, the composition may be administered orally.
- In some embodiments, prior to administration, the composition may be sprinkled on food or nutrient that is solid, semi-solid, or liquid; into water; or into other types of liquid drink.
- A study was performed to prepare and assess a composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 3 below. The particles were prepared using the top spray fluid bed granulation process according to embodiments of the invention.
-
TABLE 3 Composition of Example 1. % of Total Component Function Weight Granulating THC Active in 5.54 liquid (20% Dronabinol in solubilizing agent Ethanol) Kolliphor ® EL Surfactant/ 0.2 emulsifying agent Granulating CBD Active 11.08 liquid Sesame oil Solubilizing agent 8.6 Polysorbate 80 Surfactant/ 6 emulsifying agent Intra-granular Pharmatose ® Diluent 45.28 Excipient 200M (EU) (Milled Lactose Monohydrate) Kollidon ® 30Binder 3 Vivapur ® 101 Disintegrant 20.3 (Microcrystalline Cellulose) Granulation Methanol Processing solvent Non-residual Process Purified water Processing solvent Non-residual TOTAL 100 - The particle size distribution of the composition, shown in
FIG. 3 , was obtained using dynamic light scattering technique (Malvern Instruments, USA). As shown in the figure, over 70% of the particles are between about 100 □m and about 700 □m in diameter. - SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in
FIGS. 4A and 4B . - A dissolution test was performed using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots. The resulting dissolution profiles for both the THC particles and the CBD particles are shown in
FIG. 5 . Dissolution of both the THC particles and CBD particles exhibited an immediate release dissolution profile. - A study was performed to prepare and assess a composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 4 below. The particles were prepared using the high-shear granulation process with the CPS technology according to embodiments of the invention.
-
TABLE 4 Composition of Example 2. % of Total Component Function Weight Granulating THC Active in 5.54 liquid (20% Dronabinol solubilizing agent in Ethanol) Kolliphor ® EL Surfactant/ 0.2 emulsifying agent Granulating CBD Active 11.08 liquid Sesame oil Solubilizing agent 8.6 Polysorbate 80 Surfactant/ 6 emulsifying agent Intra-granular Pharmatose ® Diluent 45.28 Excipient 200M (EU) (Milled Lactose Monohydrate) Kollidon ® 30Binder 3 Vivapur ® 101 Disintegrant 20.3 (Microcrystalline Cellulose) Granulation Methanol Processing solvent Non-residual Process Purified water Processing solvent Non-residual TOTAL 100 - The particle size distribution of the composition, shown in
FIG. 6 , was obtained using dynamic light scattering technique (Malvern Instruments, USA). As shown in the figure, over 70% of the particles are between about 80 □m and about 700 □m in diameter. - SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in
FIGS. 7A and 7B . - A dissolution test was performed using 1
% polysorbate 80 in distilled water as the dissolution medium in a dissolution volume of 500 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 100 rpm. The bath temperature was 37° C. - The resulting dissolution profiles for both the THC particles and the CBD particles are shown in
FIG. 8 . Dissolution of both the THC particles and CBD particles exhibited an immediate release dissolution profile. - A study was performed to prepare and assess a composition according to embodiments of the invention, in which the composition comprises both particles that comprise THC and particles that comprise CBD, as shown in Table 5 below. The particles were prepared by loading the THC and CBD onto porous bead cores according to embodiments of the invention.
-
TABLE 5 Composition of Example 3. % of Component Function Total Weight THC in sesame oil Active in solubilizing agent 14 CBD Active 1.4 Tween ® 80Surfactant/emulsifying agent 51.6 Neusilin ® US2 (Silica) Porous bead core 33 Total 100 - Particle size distribution was obtained using dynamic light scattering technique (Malvern Instruments, USA) for the composition as well as for blank porous bead cores. As shown in
FIGS. 9A and 9B , over 70% of the particles of the composition are between about 20 □m and about 200 □m in diameter (FIG. 9A ), while over 70% of the particles of the blank porous bead cores are between about 2 □m and about 100 □m in diameter (FIG. 9B ). - SEM images of the granules obtained using Electronic Scanning Microscopy Imaging technique are shown in
FIGS. 10A-10F . - A dissolution test was performed using 1
% polysorbate 80 in distilled water as the dissolution medium in a dissolution volume of 500 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 100 rpm. The bath temperature was 37° C. - The resulting dissolution profiles for both the THC particles and the CBD particles are shown in
FIG. 11 . The dissolution profile of the THC particles was nearly the same as the dissolution profile of the CBD particles, and both particles achieved 80% release in less than 20 minutes. - A study was performed to assess immediate release compositions (Reference Composition A-C) and extended release compositions (Example Compositions A-C) that comprise different surfactants. This study examined the dissolution profile of the compositions in order to assess the emulsification capacity of each surfactant, and to evaluate the drug-releasing agent in the extended release compositions.
- The immediate release compositions are particles comprising a porous silica bead core; a surrogate active ingredient, probucol; and a surfactant selected from Tween® 80 (Reference Composition A), Kolliphor® RH40 (Reference Composition B), or Kolliphor® EL (Reference Composition C). Table 6 provides a summary of these compositions, including the quantity of each component. The weight ratio of sesame oil to surfactant was 1:5 in each immediate release composition. To prepare the compositions, the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The surfactant was added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug-loaded beads.
-
TABLE 6 Summary of the components and their quantities (% w/w) of Reference Compositions A-C. Reference Reference Reference Component Composition A Composition B Composition C Probucol 1.25% 1.25% 1.25% Sesame oil 11.25% 11.25% 11.25% Surfactant 62.5% 62.5% 62.5% (Tween ® 80) (Kolliphor ® RH 40) (Kolliphor ® EL) Neusilin 25% 25% 25% US2 beads TOTAL 100% 100% 100% - The extended release compositions are particles comprising a porous silica bead core; a surrogate active ingredient, probucol; glyceryl monooleate as a gel-forming agent; and a surfactant selected from
Tween® 80 in a weight ratio of 1:1 with the glyceryl monooleate (Example Composition A), Kolliphor® RH40 in a weight ratio of 11.5:1 with the glyceryl monooleate (Example Composition B), and Kolliphor® EL in a weight ratio of about 5.25:1 with the glyceryl monooleate (Example Composition C). Table 7 provides a summary of these compositions, including the quantity of each component. To prepare the compositions, the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The surfactant and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator. -
TABLE 7 Summary of the components and their quantities (% w/w) of Example Compositions A-C. Example Example Example Component Composition A Composition B Composition C Probucol 1.3% 1.25% 1.25% Sesame oil 12% 11.25% 11.25% Glyceryl 26.7% 5% 10% monooleate Surfactant 26.7% 57.5% 52.5% (Tween ® 80) (Kolliphor ® RH 40) (Kolliphor ® EL) Neusilin 33.3% 25% 25% US2 beads TOTAL 100% 100% 100% - A dissolution test was conducted on the compositions using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each immediate release Reference Compositions A-C are provided in Table 8 and in
FIG. 12A .Surfactant Tween® 80 was able to facilitate over 80% w/w release of probucol from the Neusilin® in the dissolution medium within 15 minutes as shown in Table 8. SurfactantsKolliphor® RH 40 and Kolliphor® EL were both able to facilitate over 80% w/w release of Probucol in sesame oil from the Neusilin® silica pores in the dissolution medium within 5 minutes, as shown in Table 8. -
TABLE 8 Dissolution profile of Reference Compositions A-C. % Drug Release of Probucol Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min Reference 79 81 82 83 83 84 84 86 88 Composition A Reference 82 84 85 85 85 85 85 85 85 Composition B Reference 100 99 98 98 98 98 99 99 100 Composition C -
FIG. 12A illustrates that all the surfactants evaluated attributed greater than 80% w/w drug release in the dissolution medium. Kolliphor® EL demonstrated the highest emulsification capacity yielding a release after 24 hours of 100% w/w drug from the silica pores as compared to 85% w/w with Kolliphor® RH40 and 88% w/w withTween® 80. - The dissolution profiles of each extended release Example Composition A-C are provided in Table 9 and in
FIG. 12B . The dissolution profile of Example Composition A, in whichTween® 80 was used as the surfactant, showed that drug release was extended for the first 6 hours to achieve 50% w/w drug release—and thereby zero order release—for up to 24 hours (see Table 9 andFIG. 12B ). - The dissolution profile of Example Composition B, in which Kolliphor® RH40 was used as the surfactant, showed over 80% w/w drug release by 5 minutes (see Table 9 and
FIG. 12B ). Similarly, the dissolution profile of Example Composition C, which used Kolliphor® EL as the surfactant, showed 79% w/w drug release by 5 minutes and over 80% w/w drug release by 15 minutes (see Table 9 andFIG. 12B ). -
TABLE 9 Dissolution profile of Example Compositions A-C. % Drug Release of Probucol Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min Example 11 15 19 27 33 42 48 50 50 Composition A Example 84 87 87 88 89 89 90 90 90 Composition B Example 79 84 85 87 87 88 88 89 89 Composition C
These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of providing an extended release profile. In addition, it is hypothesized that the hydrophilicity of glyceryl monooleate may have increased the emulsification action of the beads leading to higher drug release in dissolution medium. - A study was performed to assess five extended release compositions (XR Example Compositions D-H) of particles comprising a porous silica bead core; a surrogate active ingredient, probucol; glyceryl monooleate as a gel-forming agent; and a surfactant Kolliphor® EL at varying ratios with the glyceryl monooleate. Table 10 provides a summary of these compositions, including the quantity of each component
- To prepare the compositions, the probucol was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. Kolliphor® EL and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator.
- A dissolution test was conducted on XR Example Compositions D-H using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 11 and
FIG. 13 . The dissolution profiles of XR Example Compositions D-F showed that 90% w/w or greater drug release within 5 minutes, which indicates that no extended release was achieved. The dissolution profile of XR Example Composition G exhibited 70% w/w drug release within 5 minutes, but release remained below 80% w/w through 24 hours. The dissolution profile of XR Example Composition H showed 50% w/w drug release at 5 minutes, which climbed to 80% w/w by 120 minutes. -
TABLE 10 Summary of the components and their quantities (% w/w) of XR Example Compositions D-H. XR Example XR Example XR Example XR Example XR Example Components Composition D Composition E Composition F Composition G Composition H Probucol 1.2% 1.1% 1.1% 1% 1% Sesame Oil 10.7% 10% 9.7% 9.4% 9% Glyceryl 4.7% 9% 13% 16.7% 20% monooleate Kolliphor ® 59.5% 56.8% 54.3% 52.1% 50% EL Neusilin US2 23.8% 22.7% 25% 20.1% 20% beads TOTAL 100% 100% 100% 100% 100% -
TABLE 11 Dissolution profile of XR Example Compositions D-H. % Drug Release of Probucol Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min XR Example 95 91 91 91 91 91 91 91 93 Composition D XR Example 91 91 91 91 92 92 93 93 94 Composition E XR Example 90 92 92 93 94 93 94 94 94 Composition F XR Example 70 76 77 77 77 78 78 78 79 Composition G XR Example 50 66 72 78 80 79 79 81 81 Composition H - These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of providing an extended release profile.
- A study was performed to compare an immediate release composition (IR Reference Composition D) and an extended release composition (XR Example Composition I) of particles comprising a porous silica bead core; cannabinoid THC; and
surfactant Tween® 80. The particles of the extended release composition additionally comprise glyceryl monooleate as a gel-forming agent. Table 12 provides a summary of these compositions, including the quantity of each component. - To prepare the IR Reference Composition D, the THC was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator. - To prepare the XR Example Composition I, the THC was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator. - A dissolution test was conducted on IR Reference Composition D and XR Example Composition I using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 13 and
FIGS. 14A and 14B . The dissolution profile of IR Reference Composition D showed 80% w/w THC release after 5 minutes, and about 100% w/w THC release by 12 hours (see Table 13 andFIG. 14A ). In contrast, the dissolution profile of XR Example Composition I showed less than 20% w/w THC release after 5 minutes, and less than 60% w/w drug release after 12 hours (see Table 13 andFIG. 14B ). -
TABLE 12 Summary of the components and their quantities (% w/w) of IR Reference Composition D and XR Example Composition I. IR Reference XR Example Component Composition D Composition I THC in sesame oil 1.4% 1.4% Sesame oil 12.6% 12.6% Surfactant Tween ® 8053% 26.5% Capmul GMO-50 — 26.5% (glyceryl monooleate) Neusilin US2 beads 33% 33 % TOTAL 100% 100% -
TABLE 13 Dissolution profile of IR Reference Composition D and XR Example Composition I. % Drug Release of THC Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min IR Reference 80 92 93.5 95.5 96.5 98 97.5 100 Composition D XR Example 17.5 22.5 26.5 32 41 49.5 55.5 56 Composition I - These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of extending the release of THC.
- A study was performed to compare an immediate release composition (IR Reference Composition E) and an extended release composition (XR Example Composition J) of particles comprising a porous silica bead core; cannabinoid CBD; and
surfactant Tween® 80. The particles of the extended release composition additionally comprise glyceryl monooleate as a gel-forming agent. Table 14 provides a summary of these compositions, including the quantity of each component. - To prepare the IR Reference Composition E, the CBD was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin US2 silica beads using a high shear granulator. - To prepare the XR Example Composition J, the CBD was added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator. - A dissolution test was conducted on IR Reference Composition E and XR Example Composition J using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 15 and
FIGS. 15A and 15B . The dissolution profile of IR Reference Composition E showed over 70% w/w CBD release after 5 minutes, and over 90% w/w CBD release by 15 minutes (see Table 15 andFIG. 15A ). In contrast, the dissolution profile of XR Example Composition J showed less than 25% w/w CBD release after 5 minutes, and less than 70% w/w CBD release after 12 hours (see Table 15 andFIG. 15B ). -
TABLE 14 Summary of the components and their quantities (% w/w) of IR Reference Composition E and XR Example Composition J. IR Reference XR Example Component Composition E Composition J CBD 1.4% 1.4% Sesame oil 12.6% 12.6% Surfactant Tween ® 8053% 26.5% Capmul GMO-50 — 26.5% (glyceryl monooleate) Neusilin US2 beads 33% 33 % TOTAL 100% 100% -
TABLE 15 Dissolution profile of IR Reference Composition E and XR Example Composition J. % Drug Release of CBD Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min IR Reference 78 94.5 96.5 97.5 98.5 99 100 101 Composition E XR Example 21.5 29.5 36 44 52.5 56.5 60 64 Composition J - These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of extending the release of CBD.
- A study was performed to compare an immediate release composition (IR Reference Composition F) and an extended release composition (XR Example Composition K) of particles comprising a porous silica bead core; cannabinoids THC and CBD; and
surfactant Tween® 80 in a capsule. The particles of the extended release composition additionally comprise glyceryl monooleate as a gel-forming agent. Table 16 provides a summary of these compositions, including the quantity of each component. - To prepare the IR Reference Composition F, the THC and CBD were added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 was added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator, and resulting particles were placed in a capsule. - To prepare the XR Example Composition K, the THC and CBD were added to sesame oil in a glass beaker, and a sonicator was used to obtain a uniform mixture. The
surfactant Tween® 80 and the glyceryl monooleate were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then loaded into pores of the Neusilin® US2 silica beads using a high shear granulator, and resulting particles were placed in a capsule. - A dissolution test was conducted on IR Reference Composition F and XR Example Composition K using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 17 (for release of THC of both compositions) and Table 18 (for release of CBD of both compositions) and in
FIG. 16A (release of THC and CBD in IR Reference Composition F) andFIG. 16B (release of THC and CBD in XR Example Composition K). The dissolution profile of IR Reference Composition F showed, for both THC and CBD, over 60% w/w release within 30 minutes, and over 90% w/w release by 12 hours (see Tables 17 and 18, andFIG. 16A ). In contrast, the dissolution profile of XR Example Composition K showed, for both THC and CBD, less than 5% w/w release after 30 minutes, and less than 60% w/w release after 12 hours (see Tables 17 and 18, andFIG. 16B ). -
TABLE 16 Summary of the components and their quantities (% w/w) of IR Reference Composition F and XR Example Composition K. IR Reference XR Example Component Composition F Composition K THC in sesame oil 14% 14% CBD 1.4% 1.4% Surfactant Tween ® 8053% 26.5% Capmul GMO-50 — 26.5% (glyceryl monooleate) Neusilin US2 beads 33% 33 % TOTAL 100% 100% -
TABLE 17 Dissolution profile of THC of IR Reference Composition F and XR Example Composition K. % Drug Release of THC Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min IR Reference 12 54.5 72.5 76.5 78.5 81 82 92 Composition F XR Example 0.35 1.5 4 9.5 14.5 53.5 Composition K -
TABLE 18 Dissolution profile of CBD of IR Reference Composition F and XR Example Composition K. % Drug Release of CBD Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min IR Reference 14.5 59 75.5 78.5 80.5 83.5 84 95 Composition F XR Example 0.3 1.5 4 9.5 52 Composition K - These results demonstrate that glyceryl monooleate as a gel-forming agent is capable of extending the release of THC and CBD.
- An analysis was also performed to examine the impact on physical characteristics of loading THC and CBD onto the silica beads.
FIGS. 17A-17C andFIGS. 17D-17E compare the physical appearance of plain Neusilin US2 silica beads and of the particles of IR Reference Composition F, respectively. The particles loaded with THC and CBD have a more textured surface as compared to the plain Neusilin US2 silica beads. - In addition, a comparison of the particle size distribution of the plain Neusilin US2 silica beads and the particles of IR Reference Composition F is shown in
FIGS. 18A and 18B . The plain Neusilin US2 silica beads exhibited a wider distribution of particle sizes and fewer particles having a diameter of about 40 mm or larger, as compared to the particles of IR Reference Composition F (seeFIG. 18A compared toFIG. 18B ). - THC is added in sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
Tween® 80 and the gel-forming agent, glyceryl monooleate, is added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1. The resultant multiparticulates are loaded into a capsule. - CBD is added in sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
Tween® 80 and the gel-forming agent, glyceryl monooleate, is added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1. The resultant multiparticulate composition is compressed into a tablet. - THC and CBD, in combination, are added to sesame oil in a glass beaker using a sonicator to obtain a uniform mixture.
Tween® 80 and the gel-forming agent, glyceryl monooleate, are added to the mixture and mixed homogenously using a vortex mixer. The mixture is loaded into pores of the Neusilin® US2 silica beads using a high shear granulator to achieve uniform drug loaded beads.Tween® 80 is used as a surfactant with glyceryl monooleate in ratio of 1:1. The resultant multiparticulates containing CBD and THC are filled into capsules. - A study was performed to assess two different extended release compositions (XR Example Compositions L and M) of particles comprising an inert core and a coating having the following: a surrogate active ingredient, probucol; two or more release-controlling polymers; and a release-accelerating polymer. Table 19 provides a summary of these compositions, including the quantity of each component.
- To prepare the compositions, the probucol was mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers (Eudragit® RS and Ethocel® E-10 in Example Composition L; Eudragit® RS, Eudragit® RL, and Ethocel® E-10 in Example Composition M) and release-accelerating polymer (Kollidon® K30) were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then applied onto Cellets® (Glatt GmBH, Germany) in a beaker and the coated pellets were dried.
- A dissolution test was conducted on XR Example Compositions L and M using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 20 and in
FIGS. 19A and 19B . The dissolution profile of XR Example Composition L showed about 13% w/w drug release within 15 minutes and about 38% w/w drug release at 120 minutes (see Table 20 andFIG. 19A ). The amount of drug released achieved 66% w/w at 24 hours.FIG. 20 is an SEM image for the Cellets coated with probucol, the release-controlling polymer, and the release-accelerating polymer. The dissolution profile of XR Example Composition M showed about 25% w/w drug release within 2 hours and the extended release profile was maintained through 24 hours (see Table 20,FIG. 19B ). - In addition, an assay was performed on both XR Example Compositions L and M. The results are presented in Table 21.
-
TABLE 19 Summary of the components and their quantities (% w/w) of XR Example Compositions L and M. XR Example XR Example Component Composition L Composition M Probucol 14.3% 14.3% Ethanol To make 10% To make 10% solution of solution of Probucol in ethanol Probucol in ethanol and water (50:50) and water (50:50) Eudragit ® RS 14.3% 7.15% Eudragit ® RL — 7.15% Ethocel ® E-10 14.3% 14.3% Kollidon ® K30 7.1% 7.1% Cellets ® 50% 50 % TOTAL 100% 100% -
TABLE 20 Dissolution profile of XR Example Compositions L and M. % Drug Release of Probucol Composition 5 min 15 min 30 min 60 min 120 min 180 min 720 min 1440 min XR Example 8 13 23 30 38 43 59 66 Composition L XR Example 7 11 16 23 25 27 36 40 Composition M -
TABLE 21 Assay of XR Example Compositions L and M. Composition Assay XR Example Composition L 71% w/w XR Example Composition M 73% w/w - These results demonstrate that Eudragit® RS 30D and Eudragit® RL 30D can be used as release-controlling polymers in a coating to provide an extended release profile.
- A study was performed to compare an immediate release composition (IR Reference Composition F) and an extended release composition (XR Example Composition N) of particles comprising an inert core and a coating having cannabinoid THC. The coating for the particles of the extended release composition additionally comprise release-controlling polymers Eudragit® RS 30D and Eudragit® RL 30D. Table 22 provides a summary of these compositions, including the quantity of each component.
- To prepare the IR Reference Composition F, the THC was mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - To prepare the XR Example Composition N, the THC was mixed with methanol in a glass beaker to form a homogenous dispersion. The Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - A dissolution test was conducted on IR Reference Composition F and XR Example Composition N using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 23 and
FIGS. 21A and 21B . The dissolution profile of IR Reference Composition F showed nearly 70% w/w THC release after 15 minutes, and over 95% w/w THC release by 120 minutes (see Table 23 andFIG. 21A ). In contrast, the dissolution profile of XR Example Composition N showed less than 25% w/w THC release after 15 minutes, about 60% w/w THC release after 120 minutes, and less than 75% w/w THC release after 24 hours (see Table 23 andFIG. 21B ). -
TABLE 22 Summary of the components and their quantities (% w/w) of IR Reference Composition F and XR Example Composition N. IR Reference XR Example Component Composition F Composition N THC 0.5% 0.5% Methanol q.s. q.s. Eudragit ® RS 30D — 4% Eudragit ® RL 30D — 4 % Suglets ® 40/45 99.5% 91.5 % TOTAL 100% 100% -
TABLE 23 Dissolution profile of IR Reference Composition F and XR Example Composition N. % Drug Release of THC Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min IR Reference 59 69.5 80 89 95.5 99 101 103.5 105 Composition F XR Example — 22 32 44 60 70 72 73 73 Composition N - These results demonstrate that Eudragit® RS 30D and Eudragit® RL 30D can be used as release-controlling polymers in a coating to extend the release of THC.
- A study was performed to compare an immediate release composition (IR Reference Composition G) and an extended release composition (XR Example Composition O) of particles comprising an inert core and a coating having cannabinoid CBD. The coating for the particles of the extended release composition additionally comprise release-controlling polymers Eudragit® RS 30D and Eudragit® RL 30D. Table 24 provides a summary of these compositions, including the quantity of each component.
- To prepare the IR Reference Composition G, the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - To prepare the XR Example Composition O, the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion. The Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - A dissolution test was conducted on IR Reference Composition G and XR Example Composition O using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 25 and
FIGS. 22A and 22B . The dissolution profile of IR Reference Composition G showed nearly 80% w/w CBD release after 5 minutes, and over 90% w/w CBD release by 15 minutes (see Table 25 andFIG. 22A ). In contrast, the dissolution profile of XR Example Composition O showed less than 20% w/w CBD release through 60 minutes and less than 40% w/w CBD release after 240 minutes, although at 24 hours there was about 100% w/w CBD release (see Table 25 andFIG. 22B ). -
TABLE 24 Summary of the components and their quantities (% w/w) of IR Reference Composition G and XR Example Composition O. IR Reference XR Example Component Composition G Composition O CBD 2% 2% Methanol q.s. q.s. Eudragit ® RS 30D — 4% Eudragit ® RL 30D — 4 % Suglets ® 40/45 98% 90 % TOTAL 100% 100% -
TABLE 25 Dissolution profile of IR Reference Composition G and XR Example Composition O. % Drug Release of CBD Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min IR Reference 78 94.5 96.5 97.5 98.5 99 100 101 Composition G XR Example — 1 2 12 20 31 — — 100 Composition O - These results demonstrate that Eudragit® RS 30D and Eudragit® RL 30D can be used as release-controlling polymers in a coating to extend the release of CBD.
- A study was performed to compare an immediate release composition (IR Reference Composition H) and an extended release composition (XR Example Composition P) of particles comprising an inert core and a coating having cannabinoids THC and CBD. The coating for the particles of the extended release composition additionally comprise release-controlling polymers Eudragit® RS 30D and Eudragit® RL 30D. Table 26 provides a summary of these compositions, including the quantity of each component.
- To prepare the IR Reference Composition H, the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - To prepare the XR Example Composition P, the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The Eudragit® RS 30D and Eudragit® RL 30D were added to the mixture, and a vortex mixer was used to form a homogenous mixture. The mixture was then applied onto
Suglets® 40/45 in a beaker and the coated pellets were dried. - A dissolution test was conducted on IR Reference Composition H and XR Example Composition P using purified water, USP, as the dissolution medium in a dissolution volume of 900 ml. A USP Type II paddle apparatus was used to mix the dissolution medium at a paddle speed of 75 rpm. The bath temperature was 37° C., and a 10-μm porous filter was used to sample aliquots.
- The dissolution profiles of each composition are provided in Table 27 (for release of THC of both compositions) and Table 28 (for release of CBD of both compositions) and in
FIG. 23A (release of THC and CBD in IR Reference Composition H) andFIG. 23B (release of THC and CBD in XR Example Composition P). The dissolution profile of IR Reference Composition H showed, for both THC and CBD, about 70% w/w or greater release within 15 minutes, and over 95% w/w release by 120 minutes (see Tables 27 and 28, andFIG. 23A ). In contrast, the dissolution profile of XR Example Composition P showed, for both THC and CBD, less than 30% w/w release after 15 minutes, and less than 70% w/w release after 120 minutes (see Tables 27 and 28, andFIG. 23B ). -
TABLE 26 Summary of the components and their quantities (% w/w) of IR Reference Composition H and XR Example Composition P. IR Reference XR Example Component Composition H Composition P THC 0.5% 0.5 % CBD 2% 2% Methanol q.s. q.s. Eudragit ® RS 30D — 4% Eudragit ® RL 30D — 4 % Suglets ® 40/45 97.5% 89.5 % TOTAL 100% 100% -
TABLE 27 Dissolution profile of THC of IR Reference Composition H and XR Example Composition P. % Drug Release of THC Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min IR Reference 59 69 79 88 98 99 100 102 104 Composition H XR Example — 21 31 48 60 70 72 73 74 Composition P -
TABLE 28 Dissolution profile of CBD of IR Reference Composition H and XR Example Composition P. % Drug Release of CBD Composition 5 min 15 min 30 min 60 min 120 min 240 min 360 min 720 min 1440 min IR Reference 79 95 97 98 99 100 100 100 101 Composition H XR Example — 1 3 15 20 32 — — 100 Composition P - These results demonstrate that Eudragit® RS 30D and Eudragit® RL 30D as release-controlling polymers can be used in a coating to extend the release of THC and CBD.
- A study was performed to examine the impact on physical characteristics assessed by SEM imaging of loading THC and CBD onto inert cores selected from Cellets and
Suglets® 40/45. - To prepare Cellets loaded with THC and CBD, the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto Cellets in a beaker and the coated pellets were dried.
- To prepare
Suglets® 40/45 loaded with THC and CBD, the THC and CBD were mixed with methanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied ontoSuglets® 40/45 in a beaker and the coated pellets were dried. -
FIGS. 24A-24C andFIGS. 24D-24E compare the physical appearance of plain Cellets and of Cellets coated with THC and CBD, respectively. The Cellets loaded with THC and CBD have the appearance of coated surface morphology as compared to the plain Cellets. -
FIGS. 25A-25C andFIGS. 25D-25E compare the physical appearance of plain Suglets® 40/45 and ofSuglets® 40/45 coated with THC and CBD, respectively. TheSuglets® 40/45 loaded with THC and CBD have the appearance of coated surface morphology as compared to theplain Suglets® 40/45. - A study was performed to examine the impact on particle size distribution of loading CBD onto inert cores selected from Cellets and
Suglets® 40/45. - To prepare Cellets loaded with CBD, the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied onto Cellets in a beaker and the coated pellets were dried.
- To prepare
Suglets® 40/45 loaded with CBD, the CBD was mixed with ethanol in a glass beaker to form a homogenous dispersion. The dispersion was then applied ontoSuglets® 40/45 in a beaker and the coated pellets were dried. -
FIGS. 26A and 26B compare the particle size distribution of the plain Cellets and the Cellets loaded with CBD. As shown in these figures, there was no notable difference in particle size distribution between the plain Cellets and the Cellets loaded with CBD. -
FIGS. 27A and 27B compare the particle size distribution of theplain Suglets® 40/45 and theSuglets® 40/45 loaded with CBD. As shown in these figures, theplain Suglets® 40/45 exhibited a slightly wider distribution of particle sizes as compared to theSuglets® 40/45 coated with CBD. - THC is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 is added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried. The multiparticulates are then filled into a No. 2 capsule.
- CBD is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried. The multiparticulates are then formed into a tablet.
- THC and CBD, in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried. The multiparticulates are then provided in a sachet.
- THC is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried. The multiparticulates are then formed into tablets.
- CBD is mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried. The resultant multiparticulates are then provided in a capsule, which is opened and admixed with apple sauce prior to administration.
- THC and CBD, in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS, Eudragit® RL, and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried.
- CBD and the antipsychotic agent clozapine are dissolved in a hydroalcoholic solution comprising ethanol, and then mixed with
Tween® 80. The mixture is loaded onto Neusilin® US2 (Silica) and mixed homogenously using a vortex mixer to obtain immediate release particles. - THC and CBD, in combination in sesame oil, are sprayed onto Pharmatose® 200M (EU) (Milled Lactose Monohydrate),
Kollidon® 30, and Vivapur® 101 (Microcrystalline Cellulose) in a graulator bowl, and the mixture undergoes fluid bed granulation. The resulting granules are sized, milled, and screened to generate immediate release particles. - THC and CBD, in combination, are mixed with ethanol and water (50:50) in a glass beaker to form a homogenous dispersion. The release-controlling polymers Eudragit® RS and Ethocel® E-10 along with release-accelerating polymer Kollidon® K30 are added to the mixture and mixed homogenously using a vortex mixer. The mixture is then applied onto Cellets® in a beaker and the coated pellets are dried to generate extended release particles.
- The immediate release particles and the extended release particles are then mixed together in a 50:50 ratio by weight to generate a sustained release composition.
- Although specific embodiments of the present invention have been disclosed herein, those having ordinary skill in the art will understand that changes can be made to the specific embodiments without departing from the spirit of the invention. The scope of the invention is not to be restricted, therefore, to the specific embodiments. Furthermore, it is intended that the appended claims cover any and all such applications, modifications, and embodiments within the scope of the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/081,189 US20210038520A1 (en) | 2018-07-18 | 2020-10-27 | Multiparticulate formulations of cannabinoids |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862700107P | 2018-07-18 | 2018-07-18 | |
US16/513,238 US20200046642A1 (en) | 2018-07-18 | 2019-07-16 | Multiparticulate formulations of cannabinoids |
US17/081,189 US20210038520A1 (en) | 2018-07-18 | 2020-10-27 | Multiparticulate formulations of cannabinoids |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/513,238 Division US20200046642A1 (en) | 2018-07-18 | 2019-07-16 | Multiparticulate formulations of cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210038520A1 true US20210038520A1 (en) | 2021-02-11 |
Family
ID=68344901
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/513,154 Active 2040-01-08 US11439595B2 (en) | 2018-07-18 | 2019-07-16 | Immediate release formulations of cannabinoids |
US16/512,967 Pending US20200046787A1 (en) | 2018-07-18 | 2019-07-16 | Extended release formulations of cannabinoids |
US16/513,238 Pending US20200046642A1 (en) | 2018-07-18 | 2019-07-16 | Multiparticulate formulations of cannabinoids |
US16/513,068 Pending US20200046643A1 (en) | 2018-07-18 | 2019-07-16 | Extended release formulations of cannabinoids |
US17/081,189 Pending US20210038520A1 (en) | 2018-07-18 | 2020-10-27 | Multiparticulate formulations of cannabinoids |
US17/081,170 Pending US20210052500A1 (en) | 2018-07-18 | 2020-10-27 | Multiparticulate formulations of cannabinoids |
US17/220,467 Active 2040-01-27 US11918690B2 (en) | 2018-07-18 | 2021-04-01 | Immediate release formulations of cannabinoids |
US17/880,420 Pending US20220378703A1 (en) | 2018-07-18 | 2022-08-03 | Immediate release formulations of cannabinoids |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/513,154 Active 2040-01-08 US11439595B2 (en) | 2018-07-18 | 2019-07-16 | Immediate release formulations of cannabinoids |
US16/512,967 Pending US20200046787A1 (en) | 2018-07-18 | 2019-07-16 | Extended release formulations of cannabinoids |
US16/513,238 Pending US20200046642A1 (en) | 2018-07-18 | 2019-07-16 | Multiparticulate formulations of cannabinoids |
US16/513,068 Pending US20200046643A1 (en) | 2018-07-18 | 2019-07-16 | Extended release formulations of cannabinoids |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/081,170 Pending US20210052500A1 (en) | 2018-07-18 | 2020-10-27 | Multiparticulate formulations of cannabinoids |
US17/220,467 Active 2040-01-27 US11918690B2 (en) | 2018-07-18 | 2021-04-01 | Immediate release formulations of cannabinoids |
US17/880,420 Pending US20220378703A1 (en) | 2018-07-18 | 2022-08-03 | Immediate release formulations of cannabinoids |
Country Status (7)
Country | Link |
---|---|
US (8) | US11439595B2 (en) |
EP (4) | EP3823596A2 (en) |
CN (6) | CN112770726B (en) |
AU (4) | AU2019306787A1 (en) |
BR (4) | BR112021001323A2 (en) |
CA (4) | CA3108216A1 (en) |
WO (4) | WO2020016658A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021263132A1 (en) | 2020-06-26 | 2021-12-30 | Aprecia Pharmaceuticals LLC | Rapidly-orodispersible tablets having an interior cavity |
WO2023002196A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Constituent, derivative or extract of cannabis in a water soluble matrix |
WO2023002199A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Composition comprising a constituent, derivative or extract of cannabis |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020016658A2 (en) * | 2018-07-18 | 2020-01-23 | Glatt Gmbh | Immediate release formulations of cannabinoids |
WO2020092352A1 (en) * | 2018-10-30 | 2020-05-07 | Kelsie Biotech, Llc | Tablets, formulations and methods for low melting point active ingredients |
US20220096398A1 (en) * | 2019-01-31 | 2022-03-31 | Macquarie University | Complexes and compositions comprising probucol and uses thereof |
CA3040547C (en) * | 2019-04-17 | 2021-12-07 | Medcan Pharma A/S | Cannabinoid lozenge formulation |
US20210290564A1 (en) * | 2020-03-17 | 2021-09-23 | Tauriga Sciences Inc. | Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment |
WO2021228366A1 (en) * | 2020-05-11 | 2021-11-18 | Add Advanced Drug Delivery Technologies Ltd. | Uses and formulations of cannabinoids |
AU2021270970A1 (en) * | 2020-05-11 | 2022-12-15 | Add Advanced Drug Delivery Technologies Ltd. | Uses and formulations of cannabinoids |
US11752185B2 (en) | 2020-05-29 | 2023-09-12 | Hemp Corporation | Powderized cannabis oil |
EP4164613A1 (en) * | 2020-06-20 | 2023-04-19 | Chavan, Neha | Compositions for solubilizing water-insoluble active ingredients |
CN111804166B (en) * | 2020-08-19 | 2021-05-04 | 浙江新维士生物科技有限公司 | Anti-leakage low-temperature ingredient production process for suspension soft capsules |
IT202000027408A1 (en) * | 2020-11-16 | 2022-05-16 | Indena Spa | CANNABIDIOL SOLID DISPERSIONS |
WO2022148672A1 (en) * | 2021-01-08 | 2022-07-14 | Société des Produits Nestlé S.A. | Oral solid cannabinoid oil composition for treating central nervous system disorders |
WO2023002200A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Constituent, derivative or extract of cannabis in amorphous form |
WO2023002195A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Methods of preparing compositions comprising a constituent, derivative or extract of cannabis |
WO2023166409A1 (en) * | 2022-03-04 | 2023-09-07 | Buzzelet Development And Technologies Ltd. | Compositions comprising at least one of a terpene and a cannabinoid and uses thereof |
GB2618322A (en) * | 2022-04-29 | 2023-11-08 | 113 Botanicals Ltd | Compositions and methods |
WO2024033521A1 (en) * | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018035030A1 (en) * | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | Time release fat-soluble actives |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
WO2000018500A1 (en) | 1998-09-24 | 2000-04-06 | Glatt Systemtechnik Dresden Gmbh | Device for producing a pourable product and a method for using said device |
US6328992B1 (en) | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
US5891496A (en) | 1997-08-06 | 1999-04-06 | Hannah; Scott C. | Fat-free chopped and formed potato products and process |
GB9726916D0 (en) | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
AU3697200A (en) | 1999-02-04 | 2000-08-25 | New Millennium Pharmaceutical Research, Inc. | Method for enhancement of delivery of thc by the administration of its prodrugs via the nasal route |
DE10004939C1 (en) | 2000-02-05 | 2001-08-23 | Lothar Moerl | Gas flow unit, for jet layer apparatus, comprises jet inlet wall, return flow wall, cylinder, and fluidizing chamber |
NZ527289A (en) | 2001-02-14 | 2005-05-27 | Gw Pharma Ltd | Lipophilic medicaments and their administration via mucosal surfaces |
GB0103638D0 (en) * | 2001-02-14 | 2001-03-28 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
DE10162781A1 (en) | 2001-12-20 | 2003-07-03 | Glatt Ingtech Gmbh | Jet layer apparatus used for continuous and batch processes comprises process regions joined together by overflows |
US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
CN1747822A (en) | 2002-12-10 | 2006-03-15 | Cps奥罗瑟尔有限责任公司 | Method of preparing biologically active formulations |
DE10322062A1 (en) | 2003-05-15 | 2004-12-02 | Glatt Ingenieurtechnik Gmbh | Method and device for applying liquids in a solid flow of a spouted bed apparatus |
TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
DE102005037630A1 (en) | 2005-08-09 | 2007-02-15 | Glatt Gmbh | Process for the preparation of particles of pharmaceutical substances, particles of pharmaceutical substances and their use |
WO2008021394A2 (en) * | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
WO2009007768A1 (en) * | 2007-07-06 | 2009-01-15 | Gumlink A/S | Compressed tablet comprising polyol |
EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
WO2011063164A2 (en) * | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
US20180264013A1 (en) * | 2010-07-08 | 2018-09-20 | Wellesley Pharmaceuticals, Llc | Composition and methods for treating sleep disorders |
WO2012048045A1 (en) * | 2010-10-05 | 2012-04-12 | Jb Therapeutics, Inc. | Compositions, dosages, and methods of using tetrahydrocannabinol derivatives |
US20120231083A1 (en) * | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
US20140186491A1 (en) * | 2011-07-05 | 2014-07-03 | Kraft Foods R & D, Inc. | Bitterness masking |
CN104363890B (en) * | 2012-05-07 | 2018-01-26 | 回音制药公司 | Particulate matter containing cannboid and preparation method thereof and the oral administration unit containing the particulate matter |
GB201304662D0 (en) * | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
WO2015040212A1 (en) * | 2013-09-20 | 2015-03-26 | Tillotts Pharma Ag | Delayed release pharmaceutical formulation |
US20160022627A2 (en) | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
US20160030345A1 (en) * | 2014-08-01 | 2016-02-04 | Johnson & Johnson Consumer Inc. | Core Compositions |
MX2017003561A (en) | 2014-08-22 | 2017-08-28 | Medipath Inc | Compositions and methods for cannabinoid coatings for use in drug delivery. |
CA3089686A1 (en) * | 2015-03-10 | 2016-09-15 | Nanosphere Health Sciences, Llc | A nanoparticle drug delivery comprising liquid lipids and cannabinoids encapsulated in a single layer of essential phospholipids |
WO2016205923A1 (en) | 2015-06-25 | 2016-12-29 | Compressed Perforated Puck Technologies Inc. | Ingestible plant source pill and method |
EP4279071A3 (en) * | 2015-10-26 | 2024-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Novel cannabinoid formulations |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
EP3463287A1 (en) * | 2016-05-27 | 2019-04-10 | MedCan Pharma A/S | Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin |
CA3036585A1 (en) | 2016-09-27 | 2018-04-05 | CannTab Therapeutics Limited | Sustained release cannabinoid formulations |
JP2019530717A (en) | 2016-10-12 | 2019-10-24 | コロンビア ケア エルエルシー | Oral composition of extracted cannabinoids and method of use thereof |
WO2018132893A1 (en) * | 2017-01-23 | 2018-07-26 | CannTab Therapeutics Limited | Immediate release cannabidiol formulations |
WO2019159174A1 (en) * | 2018-02-16 | 2019-08-22 | Icdpharma Ltd. | Colonic delivery of cannabinoids in solid solution compositions |
WO2020016658A2 (en) * | 2018-07-18 | 2020-01-23 | Glatt Gmbh | Immediate release formulations of cannabinoids |
-
2019
- 2019-07-16 WO PCT/IB2019/000857 patent/WO2020016658A2/en unknown
- 2019-07-16 EP EP19795311.0A patent/EP3823596A2/en active Pending
- 2019-07-16 AU AU2019306787A patent/AU2019306787A1/en active Pending
- 2019-07-16 CN CN201980060778.2A patent/CN112770726B/en active Active
- 2019-07-16 EP EP19798700.1A patent/EP3823598A2/en active Pending
- 2019-07-16 US US16/513,154 patent/US11439595B2/en active Active
- 2019-07-16 CA CA3108216A patent/CA3108216A1/en active Pending
- 2019-07-16 CN CN202410185468.6A patent/CN118105350A/en active Pending
- 2019-07-16 WO PCT/IB2019/000860 patent/WO2020016659A2/en unknown
- 2019-07-16 WO PCT/IB2019/000847 patent/WO2020016656A2/en unknown
- 2019-07-16 CA CA3108214A patent/CA3108214A1/en active Pending
- 2019-07-16 US US16/512,967 patent/US20200046787A1/en active Pending
- 2019-07-16 EP EP19795312.8A patent/EP3823597A2/en active Pending
- 2019-07-16 CN CN201980062168.6A patent/CN112888429A/en active Pending
- 2019-07-16 US US16/513,238 patent/US20200046642A1/en active Pending
- 2019-07-16 CN CN202410185193.6A patent/CN118340729A/en active Pending
- 2019-07-16 AU AU2019304570A patent/AU2019304570A1/en active Pending
- 2019-07-16 BR BR112021001323-7A patent/BR112021001323A2/en unknown
- 2019-07-16 AU AU2019307847A patent/AU2019307847A1/en active Pending
- 2019-07-16 BR BR112021001350-4A patent/BR112021001350A2/en unknown
- 2019-07-16 EP EP19794629.6A patent/EP3823595A1/en active Pending
- 2019-07-16 BR BR112021001345-8A patent/BR112021001345A2/en unknown
- 2019-07-16 CA CA3108112A patent/CA3108112A1/en active Pending
- 2019-07-16 CN CN201980060903.XA patent/CN112739328B/en active Active
- 2019-07-16 US US16/513,068 patent/US20200046643A1/en active Pending
- 2019-07-16 CN CN201980060980.5A patent/CN112770727B/en active Active
- 2019-07-16 AU AU2019307846A patent/AU2019307846A1/en active Pending
- 2019-07-16 WO PCT/IB2019/000840 patent/WO2020016653A1/en active Application Filing
- 2019-07-16 BR BR112021001326-1A patent/BR112021001326A2/en unknown
- 2019-07-16 CA CA3108215A patent/CA3108215A1/en active Pending
-
2020
- 2020-10-27 US US17/081,189 patent/US20210038520A1/en active Pending
- 2020-10-27 US US17/081,170 patent/US20210052500A1/en active Pending
-
2021
- 2021-04-01 US US17/220,467 patent/US11918690B2/en active Active
-
2022
- 2022-08-03 US US17/880,420 patent/US20220378703A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018035030A1 (en) * | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | Time release fat-soluble actives |
Non-Patent Citations (3)
Title |
---|
Fuji Chemical Industries, 2015, The Specialty Excipient (Year: 2015) * |
Hossain, "Porous calcium phosphate glass microspheres for orthobiologic applications", May 2018, Acta Biomaterialia, 72, 396-406 (Year: 2018) * |
Volodkin, "CaCO3 templated micro-beads and -capsules for bioapplications", 2014, Advances in Colloid and Interface Science, 207, 306-324 (Year: 2014) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021263132A1 (en) | 2020-06-26 | 2021-12-30 | Aprecia Pharmaceuticals LLC | Rapidly-orodispersible tablets having an interior cavity |
US11433022B2 (en) | 2020-06-26 | 2022-09-06 | Aprecia Pharmaceuticals LLC | Rapidly-orodispersible tablets having an in interior cavity |
WO2023002196A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Constituent, derivative or extract of cannabis in a water soluble matrix |
WO2023002199A1 (en) * | 2021-07-22 | 2023-01-26 | Nicoventures Trading Limited | Composition comprising a constituent, derivative or extract of cannabis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210038520A1 (en) | Multiparticulate formulations of cannabinoids | |
US20080248107A1 (en) | Controlled Release Formulation | |
WO2003103637A2 (en) | Modified release, multiple unit drug delivery systems | |
AU2019329905B2 (en) | Vitamin D pediatric dosage forms, methods of making and using | |
JP2014516961A (en) | Multiparticulate pharmaceutical composition | |
WO2011033024A1 (en) | Controlled release composition comprising levetiracetam | |
EP2277511A1 (en) | Extended release pharmaceutical compositions of levetiracetam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: GLATT GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOWAK, REINHARD;IQBAL, ZAFAR;TALEB, MOHAMMED;AND OTHERS;SIGNING DATES FROM 20190923 TO 20200316;REEL/FRAME:056157/0626 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |